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Abstract
This dissertation includes four papers with each distributed in one chapter.
In chapter 1, I compared the performance of eight multivariate phenotype association tests.
The motivation to conduct this power comparison paper is as follows. For nearly 15 years,
genome-wide association studies (GWAS) have been widely used to identify genetic
variants associated with human diseases and traits. GWAS typically investigate genetic
variants for a predefined phenotype, thus fail to identify weak but important effects. In
recent years, many multivariate association tests have been developed. However, there is a
lack of comprehensive summary of such kinds of approaches. To fill this important gap, I
did this power comparison work. The results show that none of the methods is consistently
more powerful than that of others. Relatively more powerful methods are still in large
demanding.
In chapter 2, I proposed a Weighted Combination of multiple Phenotypes approach
(WCmulP) for testing multiple correlated phenotypes and one genetic variant of interest.
WCmulP linearly combines the multiple phenotypes with optimal weights such that the
score test statistic is maximized. I compare WCmulP with other widely used tests and
conduct extensive simulation studies as well as real data analysis to evaluate the
performance of these methods. The results show that WCmulP outperforms the compared
methods in most of the simulation scenarios and real data analysis.
As the availability of electronic health record (EHR), thousands of clinical phenotypes can
be measured and collected systematically. As a result, the phenome-wide association
studies (PheWAS) emerged to detect variants with a broad spectrum of phenotypes.
However, the current PheWAS are intrinsically univariate test, which investigate the
phenotype one at a time. Genuine PheWAS that simultaneously test the wide range of
phenotypes need to be discovered. In chapter 3, I proposed a novel PheWAS approach,
which referred to as PheCLC (PheWAS using clustering linear combination), to examine
genetic variation associated with up to thousands of phenotypes. PheCLC jointly analyzes
a wide spectrum of human phenotypes as well as classifies them into different categories
based on the International Classification of Diseases (ICD) codes. The simulation results
show that PheCLC certainly controls type I error rates and is much more powerful than the
traditional multivariate approaches.
To date, GWAS have published thousands of common variants associated with human
diseases. However, these common variants only contribute a small portion of the
phenotypic variance. Many studies showed that rare variants could substantially explain
missing heritability. In chapter 4, I derived a rare variant association study for family-based
designs, where the rare variants can be enriched compared to population-based designs. I
applied the proposed method as well as the other two family-based tests to the genetic
analysis workshop 19 (GAW19) dataset and the results show that our method can identify
more genes with power greater than 40% than the other two methods.

x

1 Chapter 1
Power Comparisons of Methods for Joint Association Analysis of Multiple
Phenotypes
Background/Aims: Genome-wide association studies (GWAS) have identified many
variants that each affects multiple phenotypes, which suggests that pleiotropic effects on
human complex phenotypes may be widespread. Therefore, statistical methods that can
jointly analyze multiple phenotypes in GWAS may have advantages over analyzing each
phenotype individually. Several statistical methods have been developed to utilize such
multivariate phenotypes in genetic association studies, however the performance of these
methods under different scenarios is largely unknown. Methods: In this study, we evaluate
the performance of some of the existing methods for association studies using multiple
phenotypes, which include O’Brien’s method, cross-validation method, optimal weight
method, TATES, PCH, CCA, MANOVA and MultiPhen. We use simulation studies to
compare the powers of these methods under a variety of scenarios, including different
numbers of phenotypes, different values of between-phenotype correlation, different minor
allele frequencies, and different mean and variance models. Results: Our simulation results
show that there is no single method that has consistently good performance among all the
scenarios. Each method has its own advantages and disadvantages. Conclusion: Our goal
of this study is to provide researchers with useful guidelines on selecting statistical methods
in the application of real data with multiple phenotypes.

1.1 Introduction
Currently, the analyses of most genome-wide association studies (GWAS) have been
performed on a single phenotype. However, in the study of a complex disease, several
correlated phenotypes may be measured for a disorder or its risk factors (Yang et al., 2010).
For example, hypertension is measured by systolic blood pressures (SBP) and diastolic
blood pressures (DBP), those two blood pressure indexes frequently display a linear
relationship (Gavish et al., 2008); people’s cognitive ability is usually measured by
memory, intelligence, language, executive function, visual-spatial function, and motor,
some of those six measurements might have relationship (Locke et al., 2006). The
correlation among those multiple phenotypes can be leveraged to improve the power of
genetic association tests to identify genetic markers associated with one or more
phenotypes (Aschard et al., 2014).
It is not always clear how to best exploit the information to increase the power of detecting
genetic markers that are associated with multiple phenotypes (Yang et al., 2010). One
available method is the standard univariate association test, which performs one phenotype
at a time (O’Reilly et al., 2012). However, analyzing each phenotype separately will suffer
penalties from the multiple testing and result in a reduced power (Yang et al., 2010).
1

Recently, several methods are introduced to detect association using multivariate
phenotypes (Yang et al., 2010; O’Reilly et al., 2012; O’Brien, 1984; van der Sluis et al.,
2013; Klei et al., 2008; Ferreira and Purcell, 2009). These multivariate analyses of
phenotypes offer several advantages over analyzing each phenotype separately (Aschard
et al., 2014; Zhou and Stephens, 2014; Stephens, 2013; Yang and Wang, 2012; Solovieff
et al., 2013; Galesloot et al., 2014). First, joint analyses of correlated phenotypes can
exploit the correlation among phenotypes (Yang and Wang, 2012). Second, most
multivariate procedures can perform a single test for association with a set of phenotypes,
which reduces the number of performed tests and alleviates the multiple testing burden
compared to analyzing all phenotypes separately (Klei et al., 2008; Zhu and Zhang, 2009).
Finally, in case of presence of pleiotropy, where a single genetic marker is associated with
multiple phenotypes, a multivariate analysis of phenotypes is more consistent with biology
compared to cross-phenotype comparison of univariate analysis (Chavali et al., 2010). In
summary, modeling multivariate phenotypes may increase the power over analyzing
individual phenotype separately in genetic association studies (Yang et al., 2010; Klei et
al., 2008; Lange et al., 2004).
Several methods to detect association using multivariate phenotypes have been introduced
in recent years. These methods can be divided into three groups: combining test statistics
from univariate analysis, variable reduction methods, and regression models (Yang and
Wang, 2012). The first group includes O’Brien’s method (OB) (O’Brien, 1984), crossvalidation method (CV) (Yang et al., 2010), and Trait-based Association Test that uses
Extended Simes procedure (TATES) (van der Sluis et al., 2013). Specifically, each method
in this group is to perform univariate phenotype-genotype association test for each
phenotype individually and then combine the test statistics from the univariate analysis
(Yang et al., 2010; O’Brien, 1984; van der Sluis et al., 2013; Wei and Johnson, 1985).
Variable reduction methods derive a single or a few new phenotypes that are linear
combinations of the original phenotypes. The best-known method for variable reduction
methods involves using one or more of the principal components of phenotypes (PCP) in
place of the original phenotypes (Lan et al., 2003; Wang and Abbott, 2008). Building on
the work of PCP, Klei et al. (2008) developed principal component of heritability (PCH)
with coefficients maximizing the heritability of phenotypes. Another variable reduction
method is canonical correlation analysis (CCA), which extracts the linear combination of
phenotypes that explain the largest possible amount of the covariation between the genetic
marker and all phenotypes (Ferreira and Purcell, 2009). Regression models, such as
multivariate analysis of variance (MANOVA) and proportional odds logistic regression for
joint model of multiple phenotypes (MultiPhen) (O’Reilly et al., 2012), can be used to
analyze the association of a genetic marker with multivariate phenotypes.
Even though several methods have been developed to jointly analyze multiple phenotypes
including the above mentioned methods, there is a lack of thorough comparison between
those methods. Each of the methods attains its maximal power only in special
circumstances (O’Reilly et al, 2012; van der Sluis et al., 2013). Therefore, a thorough
2

power comparison of these methods is a meaningful and worthy work. In this article, we
compare the power performance of eight methods in a variety of models. These eight
methods include OB (O’Brien, 1984), CV (Yang et al., 2010), optimal weight method
(OW), TATES (van der Sluis et al., 2013), PCH (Klei et al., 2008), CCA (Ferreira and
Purcell, 2009), MANOVA, and MultiPhen (O’Reilly et al., 2012). Our ultimate goal of this
study is to provide researchers with useful guidelines on selecting statistical methods in the
application of real data with multiple phenotypes.

3

1.2 Comparison of Methods
In this section, we briefly introduce each of those methods compared in this study. We use
the following notations. Considering a sample of unrelated individuals, each individual
has been genotyped at a genetic marker. Assume that there are possibly correlated
, ,…,
be a vector of univariate test statistics, where
phenotypes. Let
1, 2, … ,
is a test statistic for testing the association between a genetic marker
and the
phenotype. Assume that
asymptotically follows a multivariate normal
, ,…,
and (known or consistently estimated)
distribution with mean
covariance matrix . The null hypothesis is :
, and the alternative hypothesis is
: at least one
0 for
1, … , .
O’Brien’s method (OB). O’Brien (1984) showed that if
⋯
, the test
is the most powerful test among a class of test statistics that are linear
statistic
combination of , , … , , where
1,1 … ,1 with length (O’Brien, 1984; Wei
and Johnson, 1985). Under the null hypothesis, the test statistic
follows a normal
.
distribution with mean 0 and variance
Cross-validation method (CV). CV (Yang et al., 2010) averages multiple sample splitting
results. In detail, splitting the sample into two subsets, one is called training set for
estimating weights and the other is called testing set for constructing final testing statistic.
Let
and denote the test statistic obtained from the training set and testing set,
respectively. Then, the test statistic to test the association between a marker and multiple
phenotypes is given by
. The splitting procedure is repeated times (e.g., 100
∑
, where is the test statistic based on
times), the final test statistic is ̅
the
splitting procedure. The P-value of the final test statistic is calculated using a
permutation procedure.
Optimal weight method (OW). The above two methods are seeking a weight vector such
that
can combine the univariate test statistics in a linear manner.
is
proposed in the OB method while
is proposed in the CV method. For any
vector that may not depend on the data at hand,
follows a chi-square
distribution with degree of freedom 1 under the null hypothesis. If we consider to choose
that depends on the data at hand, we can find
such that
max
. We can
use
denote
max

as a test statistic, which we call it the optimal weight method (OW). If we
,

then

the

optimal

weight

statistic

. Under the null hypothesis,

max
follows a

chi-square distribution with degrees of freedom .

4

Trait-based Association Test that uses Extended Simes procedure (TATES). TATES (van
der Sluis et al., 2013) combines P-values obtained in standard univariate GWAS to acquire
one phenotype-based P-value, while correcting for correlations between phenotypes. In
detail, after obtaining the univariate P-values , … ,
from the corresponding univariate
association tests, those P-values are sorted in ascending order,
,…,
. Then, we can
find the effective number of independent P-values of all phenotypes,
, and the
effective number of P-values among the top P-values ,
, where
1, … , .
Finally, the ultimate P-value is given by

.

Multivariate analysis of variance (MANOVA). Since we only consider one genetic marker
in this study, one-way MANOVA is performed. Specifically, the Wilks’ lambda test is used
to conduct a hypothesis test. The Wilks’ lambda test statistic is equivalent to the likelihood
| |
, where is the
ratio test statistic, which is the ratio of the generalized variances |
|
hypothesis sum of squares and cross product (SSCP) matrix, is the error SSCP matrix,
and |∙| is the determinant of a matrix. The explicit forms of and are given by
,
, where
, is the
1 vector of
genotypes for all individuals, and is the
matrix of phenotypes for all individuals.
| |
Under , 2 log Λ
log |
has an asymptotic
distribution, where Λ denotes
|
the ratio of the likelihood function under null hypothesis to the likelihood function under
alternative hypothesis.
Principal components of heritability (PCH). Variable reduction approach derives a single
or a few new phenotypes that are linear combinations of the original phenotypes. Existing
methods include principal components analysis (PCA) where for the first component, the
coefficients maximize the variance of the multivariate phenotypes (Yang and Wang, 2012),
principal component of heritability (PCH) with coefficients maximizing the total
heritability of the phenotypes (Ott and Rabinowitz, 1999). Recently, Klei et al. (2008)
developed a PCH method, in which the sample is randomly split in a training set, which is
used to construct the optimal linear combination of phenotypes from a heritability point of
view, and a test set, which is used for association testing between genotype and the optimal
linear combination of phenotypes. The test statistic is calculated repeatedly using random
splits of the data. Ultimately, the statistic is derived from an integration of the individual
test statistics.
Canonical correlation analysis (CCA). CCA is a multivariate generalization of the
Pearson product-moment correlation (Hotelling, 1936). Ferreira and Purcell (Ferreira and
Purcell, 2009) used CCA to measure the association between the genetic marker and
phenotypes. CCA extracts the linear combination of phenotypes that explain the largest
possible amount of the co-variation between the marker and all phenotypes. The test is
based on Wilks’ lambda and the corresponding F-approximation.
5

Joint model of multiple phenotypes (MultiPhen). MultiPhen (O’Reilly et al., 2012) inverts
the general linear regression, in which the genotype is the response variable and all the
phenotypes are independent variables. The genotype data is an allele count and is therefore
modelled using ordinal regression. O’Reilly et al. (2012) used proportional odds logistic
regression model which defines the class probabilities. A likelihood ratio test is performed
to test the null hypothesis that none of the phenotypes have association with the genetic
marker.

6

1.3 Simulation Study
To compare different methods, we investigate their type-I error rates and powers by
simulation data sets with 1,000 unrelated individuals. To generate genotype data on a
genetic marker, we assume that minor allele frequency (MAF) is 0.1 or 0.3 and assume
Hardy-Weinberg Equilibrium. For each individual, we generate
10, 20 and 40
phenotypes. The phenotypes of an individual are generated from the following model
(1.1)
,…,
are the phenotypic values of an individual; is the genotypic
where
,…,
are the genetic effects of
score of the individual at the genetic marker;
the genetic marker on the phenotypes and their values depend on mean models (Table
1.1);
1
is a vector with random effect and random error , where
is a
loading matrix, the values and
depend on the variance models (Table
,…,
~
, and
,…,
~
, , where is the
1.2);
identity matrix. From the assumptions above, we can have
,…,
~
, ,
where
1
.
In our simulation studies, we consider six different mean models and two different variance
models. Table 1.1 gives the values of the genetic effect in different mean models. In
mean model 1, the genetic marker has the same size and direction of effect on all
phenotypes. In mean model 3, the genetic marker has effect on all the phenotypes, but has
different directions of the effect. In mean models 2, 4, 5, and 6, the genetic marker has
effect on part of the phenotypes, but has no effect on the rest.
The two different variance models are based on the correlation setting among all the
phenotypes. Table 1.2 gives the values of
and under the two different variance
models. Under the first variance model, all of the phenotypes have correlation with each
other. Under the second variance model, the first half phenotypes have correlation with
each other, the second half phenotypes have correlation , and there are no correlations
between phenotypes in the first half and in the second half.
The heritability of genotypes to the

phenotype is given by
var

(1.2)

∑
The heritability of genotypes to the total phenotypes is given by
∑
var
. Then given the heritability , we can calculate , , … , for different
mean models in Table 1.1.

7

For OB, CV, OW, and TATES, we use the score test statistic under the linear model as the
univariate phenotype-genotype association test. For the type-I error rates, we assume
such that the genetic marker is independent of all phenotypes. For power comparisons,
we consider different values of heritability, different values of between-phenotype
correlation, and different values of MAF.

8

1.4 Results
For type-I error rates evaluation, we consider different numbers of phenotypes, different
MAFs, different variance models, and different values of significance levels. In the two
variance models, we assume
0.1. In each simulation scenario, the sample size is 1,000,
P-values of CV and PCH are estimated by 1,000 permutations, and P-values of other
methods are calculated by asymptotic distributions. The type-I error rates are evaluated
using 1,000 replicated samples. For 1,000 replicated samples, the 95% confidence intervals
(CIs) for type-I error rates at nominal levels 0.05 and 0.01 are (0.0365, 0.0635) and (0.004,
0.016), respectively. Tables 1.3 and A.1.1-A.1.5 give the estimated type-I error rates of the
eight methods for different numbers of phenotypes (10, 20, 40), different values of MAF
(0.1, 0.3), different significance levels (0.01, 0.05), and two different variance models.
From Table 1.3 and Tables A.1.1-A.1.5, we can see that except MultiPhen, almost all the
estimated type-I error rates are within the 95% CIs, which indicates that the estimated typeI error rates are not significantly different from the nominal levels. Thus, the seven tests
are all valid tests under our simulation study. From our results, we noticed that when the
number of phenotypes is large (e.g., 40), the type-I error rates of MultiPhen are inflated.
This phenomenon is also noticed by other studies. For example, Aschart et al. (2014)
pointed out that Multiphen suffers from an inflated type-I error rates when the ratio of the
number of phenotypes over the number of individuals is relatively large (>0.01). Because
of this, we did not include MultiPhen in the power comparisons when the number of
phenotypes is 40.
For power comparisons, we consider different values of MAF, different values of betweenphenotype correlation
, different values of heritability, different numbers of
phenotypes
10, 20, 40 , different mean models, and different variance models (see
Figures 1.1-1.4 and Figures B.1.1-B.1.10). In each of the simulated scenarios, the sample
size is 1,000, P-values of CV and PCH are estimated by 1,000 permutations, and P-values
of other methods are calculated by asymptotic distributions. The power is evaluated using
1,000 replicated samples at a significance level of 0.05.
Our simulation results show the following patterns:
1. None of the considered methods are consistently most powerful under the
simulation scenarios (Figures 1.1-1.4 and B.1.1-B.1.10).
2. OW, MANOVA, CCA, PCH, and MultiPhen have very similar power over all the
simulation scenarios, and CV is consistently slightly less powerful than the five
tests (Figures 1.1-1.4 and B.1.1-B.1.10). We call the five tests (OW, MANOVA,
CCA, PCH, and MultiPhen) as group 1. The similar conclusion is also drawn in the
following published works. van der Sluis et al. (2013) pointed out that under most
circumstances, MultiPhen and MANOVA yield very similar results in terms of
power. MANOVA is equivalent to CCA when CCA is applied to a single genetic
marker at a time (Galesloot et al., 2014). The performance of Multiphen is similar
to PCH and MANOVA when a small number of phenotypes are analyzed (Aschard
9

3.

4.

5.

6.

et al., 2014). According to O’Reilly et al. (2012), MultiPhen and CCA perform very
similarly except in case of low MAF and non-normal phenotypes.
OB has the highest power among all methods when the genetic effects are
homogeneous (mean model 1). However, this method reduces power significantly
when genetic effects are heterogeneous, especially when opposite directions of the
genetic effects exist or when genotypes impact a small portion of phenotypes (mean
models 3-5). (Figures 1.1-1.4 and B.1.1-B.1.10)
Power comparisons of TATES with tests in group 1 and OB depend on the mean
models, variance models, and the values of  . In general, TATES is the most
powerful test when  is small and genotypes impact a very small portion of
phenotypes. (Figures 1.1-1.4 and B.1.1-B.1.8)
The power of OB decreases with the increasing of  because OB involves all
phenotypes and information contained by all phenotypes will be decreased with the
increasing of  ; the power of TATES is relatively robust to  because TATES
essentially only depends on the phenotype that has the strongest association with
the genotype; powers of tests in group 1 decrease or increase with the increasing of
 depending on mean models and variance models. (Figures 1.3-1.4 and B.1.5B.1.8)
Powers of all tests are robust to MAF. (Figures B.1.9-B.1.10)

The power is also evaluated at a significance level of 5×10-8 for six methods because the
two methods (CV and PCH) that use permutations to calculate their p-values are
computationally extensive. The patterns of power comparisons at significance level 5×108
(Figures B.1.11-B.1.14) are similar to those at significance level 0.05 (Figures 1.1-1.4).
In summary, tests in group 1 have very similar power, and CV is slightly less powerful
than tests in group 1. OB has the highest power among all methods when the genetic effects
are homogeneous, but this method reduces power significantly when genetic effects are
heterogeneous. In general, TATES is the most powerful test when between-phenotype
correlation  is small and genotypes impact a very small portion of the phenotypes.
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1.5 Discussion
In the study of a complex disease, several correlated phenotypes are often measured as risk
factors for the disease (Aschard et al., 2014). Analyzing multiple disease-related
phenotypes could potentially increase power to detect association of genetic markers with
a disease. In recent years, several multivariate analyses of GWAS have been introduced. A
thorough comparison between those methods is needed for researchers to choose the best
and most appropriate method under a certain circumstance. In this study, we used simulated
data to compare the performance of eight commonly used methods (OW, MANOVA,
CCA, PCH, MultiPhen, OB, CV, and TATES) for testing association between multiple
phenotypes and a genetic marker. Our simulation results showed that there is not a single
method that performs best under all the simulated scenarios we considered, each method
has its own pros and cons.
In our simulation studies, we did not study the effect of missing data. In the presence of
missing data in the outcomes, dropping individuals with missing data in the analyses may
result in power loss (Yang and Wang, 2012). Imputation can be used to impute missing
genotype data or phenotype data. Missing phenotype data can be handled either by casewise deletion (if data are missing above a pre-defined per-individual missingness
threshold) or mean imputation (i.e. a missing phenotype is replaced by the corresponding
sample mean) (Tang and Ferreira, 2012). Missing genotype data can be imputed using
dedicated software and appropriate reference panels (e.g. HapMap).
Our study showed substantially different patterns of power comparisons among our
simulated scenarios. Overall, OW, MANOVA, CCA, PCH, and MultiPhen have very
similar power, and CV is slightly less powerful than the five tests. OB has the highest
power among all methods when the genetic effects are homogeneous. TATES is the most
powerful test when between-phenotype correlation  is small and genotypes impact a
very small portion of the phenotypes. Because in practice, we do not know the number of
phenotypes impacted by genotypes and we also do not know whether the genetic effects
are homogeneous, we recommend that one can perform OB and one of the tests in group 1
when between-phenotype correlation  is large, and one can perform TATES, OB, and
one of the five tests in group 1 when between-phenotype correlation  is small. We can
also construct a robust test as follows. Let pTATES , pOB , and pOW denote the P-values of
TATES, OB, and OW, respectively. Then, we define the test statistic of the robust test as
Trobust  min  pTATES , pOB , pOW  . However, the performance of the robust test needs further
investigation.
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1.6 Tables and Figures
Table 1.1. Six mean models used in the simulation studies
Mean models
1

Phenotype number
1
⋮

Effect size (direction of the effect)

1
⋮

0
⋮

2

⋮

0

2
2
3

1
⋮

⋮

1
⋮

⋮

2
2
4

5

⋮

⋮

1
⋮

0
⋮
0

1

1
⋮
4
5

4
5
6

1

0
⋮
0
1

⋮

1
⋮
2
3

2
3

1
⋮
0
⋮
0

1
⋮

4
5

2
3

1
⋮

Note: is the total number of phenotypes; ∙ is the floor function;
indicates that
the direction of the genetic effect on the phenotype is positive (negative); given heritability,
, , … , can be calculated based on formula (2.2) in Simulation section.
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Table 1.2. The values of

and

in the two variance models.

Variance models

Values of
1,

Model 1

is a column vector with all elements 1’s, and length

with all elements 0’s, and length
simulation studies.

1, 1, … , 1

2,

Model 2

Note:

and

;

;

is a column vector

is the total number of phenotypes considered in the
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Table 1.3. Estimated type-I error rates for the eight methods under two variance models.
The total number of phenotypes is
20, MAF is 0.3, and the sample size is 1,000. is
the significance level.
Type-I error rates
Variance model 1
Methods

0.05

Variance model 2
0.01

0.05

0.01

OB

0.053

0.011

0.048

0.011

CV

0.044

0.013

0.042

0.010

OW

0.049

0.013

0.044

0.013

TATES

0.050

0.011

0.052

0.011

MANOVA

0.049

0.013

0.047

0.013

CCA

0.049

0.012

0.049

0.013

PCH

0.051

0.010

0.044

0.014

MultiPhen

0.060

0.013

0.049

0.015
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Figure 1.1. Power comparisons of the eight methods as a function of heritability for the six
mean models under variance model 1. The total number of phenotypes is
20, rho is
0.1, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure 1.2. Power comparisons of the eight methods as a function of heritability for the six
mean models under variance model 2. The total number of phenotypes is
20, rho is
0.1, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure 1.3. Power comparisons of the eight methods as a function of rho for the six mean
models under variance model 1. The total number of phenotypes is
20, heritability is
0.01, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure 1.4. Power comparisons of the eight methods as a function of rho for the six mean
models under variance model 2. The total number of phenotypes is
20, heritability is
0.01, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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2 Chapter 2
A Novel Method to Test Associations between a Weighted Combination of
Phenotypes and Genetic Variants
Many complex diseases like diabetes, hypertension, metabolic syndrome, et cetera, are
measured by multiple correlated phenotypes. However, most genome-wide association
studies (GWAS) focus on one phenotype of interest or study multiple phenotypes
separately for identifying genetic variants associated with complex diseases. Analyzing
one phenotype or the related phenotypes separately may lose power due to ignoring the
information obtained by combining phenotypes, such as the correlation between
phenotypes. In order to increase statistical power to detect genetic variants associated with
complex diseases, we develop a novel method to test a weighted combination of multiple
phenotypes (WCmulP). We perform extensive simulation studies as well as real data
(COPDGene) analysis to evaluate the performance of the proposed method. Our simulation
results show that WCmulP has correct type I error rates and is either the most powerful test
or comparable to the most powerful test among the methods we compared. WCmulP also
has an outstanding performance for identifying single-nucleotide polymorphisms (SNPs)
associated with COPD-related phenotypes.

2.1 Introduction
Genome-wide association studies (GWAS) aim to discover genetic variants associated with
complex diseases (O’Reilly et al., 2012; Yang and Wang, 2012). In GWAS, researchers
often collect data on multiple correlated phenotypes to get a better understanding of the
complex disease (Yang et al., 2010). Here are some examples of what diseases are
measured by multiple phenotypes. In type 2 diabetes (T2D) studies data are usually
collected on a number of risk factors and diabetes-related quantitative phenotypes.
Hypertension is measured by systolic blood pressures (SBP) and diastolic blood pressures
(DBP) (Yang and Wang, 2012), and the correlation coefficient between SBP and DBP was
greater than 0.5 in 95% of patients (Gavish et al., 2008). The metabolic syndrome refers to
the co-occurrence of insulin resistance, obesity, atherogenic dyslipidemia and
hypertension, and these factors are associated and share underlying mediators, pathway
and mechanisms (Huang, 2009). The correlations between multiple phenotypes can be
leveraged to improve the power of genetic association tests to identify markers associated
with one or more of the phenotypes (Aschard et al., 2014). The standard approach to
analyze these multiple correlated phenotypes is to perform single-phenotype analyses
separately and report the findings for each phenotype (O’Reilly et al., 2012). However,
analyzing one phenotype at a time will suffer penalties from the multiple testing and result
in a reduced power especially for GWAS (Yang et al., 2010). Recently, the joint analysis
of multiple phenotypes has become popular because it can increase statistical power over
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analyzing phenotypes separately in detecting genetic variants (Yang et al., 2010; Aschard
et al., 2014).
There are three commonly used strategies to detect genetic associations between a genetic
variant and multiple correlated phenotypes. The first one is combining test statistics (or pvalues) from univariate analysis. This strategy first tests an association between each
phenotype and a genetic variant individually and then combines the univariate analysis
results, i.e. test statistics or p-values, by using different approaches. The O’Brien’s method
(O’Brien, 1984), sample splitting and cross-validation method (Yang et al., 2010), Traitbased Association Test that uses Extended Simes procedure (TATES) (van der Sluis et al.,
2013), Unified Score-Based Association Test (USAT) (Ray et al., 2016), Fisher’s
Combination (Yang et al., 2016), and Adaptive Fisher’s Combination (AFC) (Liang et al.,
2016) belong to this strategy. The advantage of this strategy is its simplicity and is
especially useful for analyzing different types of phenotypes such as continuous,
dichotomous and survival (Yang and Wang, 2012). The second one is data reduction. This
strategy derives a single or a few new phenotypes that are linear combinations of the
original phenotypes. Existing methods include projection-based techniques and canonical
correlation analysis (CCA). Projection-based approaches include principal components
analysis (PCA) and principal component of heritability (PCH), where principal
components (PCs) are built to maximize either the phenotypic variance or heritability
(Yang and Wang, 2012; Aschard et al., 2014; Klei et al., 2008; Wang et al., 2016).
Canonical correlation analysis (CCA) finds the linear combination of phenotypes that
explain the largest possible amount of the correlation between the genetic variant and all
multiple phenotypes (Ferreira and Purcell, 2009). Data reduction approaches are in general
only applicable to multiple phenotypes consisting of all continuous phenotypes that are
approximately normally distributed (Yang and Wang, 2012). The third strategy is
regression models which include mixed effect models (Zhou and Stephens, 2014; Korte et
al., 2012; Casale et al., 2015), the generalized estimating equation (GEE) (Zeger and Liang,
1986; Zhang et al., 2014), and reverse regression methods (O’Reilly et al., 2012; Yan et
al., 2013; Wang et al., 2016). The linear mixed effects model (LME) and generalized linear
mixed effects model (GLMM) are two commonly used mixed effects models, where the
fixed effects are used for the genetic variant and random effects are used to account for
phenotypic correlations. The GEE methods collapse the random effects and random
residual errors in marginal regression models which are a class of models different from
mixed effect models. The reverse regression methods take genotypes as the response
variable and multiple phenotypes as predictors, such as the proportional odds logistic
regression for joint model of multiple phenotypes (MultiPhen) (O’Reilly et al., 2012).
Regression approaches are able to deal with a mixture of continuous, dichotomous, and
survival phenotypes, but they are complicated and few available software were developed
to implement these methods (Yang and Wang, 2012).
In this article, we developed a novel allele-based method for testing association between
multiple phenotypes and a genetic variant. First, we take the allele at the genetic variant as
20

the response variable and the multiple phenotypes as predictors. Then, we present a new
multivariate method that we refer to as WCmulP (Weighted Combination of multiple
Phenotypes), inspired by TOW (Test for testing the effect of an Optimally Weighted
combination of variants) procedure proposed by Sha et al. (2012) for rare variant
association studies and allele-based aproach proposed by Majumdar et al. (2015). For each
of the independent individuals, WCmulP linearly combines the multiple phenotypes to
“one phenotype” by using the optimal weights proposed by Sha et al. (2012). Then we use
the score test based on the logistic model to test the association between the genetic variant
and the linear combination of phenotypes. Using extensive simulation studies, we compare
the performance of WCmulP with some of the existing methods, MultiPhen (O’Reilly et
al., 2012), O’Brien’s method (O’Brien, 1984), TATES (van der Sluis et al., 2013), CCA
(Ferreira and Purcell, 2009), and SHet (Zhu et al., 2015). Our results show that, in all of
the simulation scenarios, WCmulP is either the most powerful test or comparable to the
most powerful tests among the methods we compared. Finally, we evaluate the
performance of our proposed method using a real data set, the COPDGene study from
dbGaP.
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2.2 Methods
We consider a sample of unrelated individuals. Each individual has possibly correlated
phenotypes. Let Yi , k denote the th phenotype of the th individual. We propose to use an
allele-based logistic regression model to test the association between a variant of interest
and multiple phenotypes. For a genetic variant with two alleles, we use
and
to
denote the coding of the two alleles of the
individual such that we use and to code
the two alleles of the first individual, use and to code the two alleles of the second
individual, and so on. For a variant with two alleles and , if the genotype of the th
individual is
, we define
1; if the genotype is , we define
0 ; and if the genotype is
, we define
1 and
0 . We define
the
phenotype corresponding to the two alleles x2 i 1 and x2i of the
individual as
y2i 1,k and y 2 i , k , where y2 i 1, k  y2 i , k  Yi , k . Hence, the total number of observations in the
allele-based data is 2 . We model the relationship between alleles and multiple phenotypes
using the inverse logistic regression model
logit

,

⋯

,

,

,

1, 2, . . . , 2 ,

(2.1)

where
Pr
1
, is the intercept, and
,…,
is
, ,…, ,
a -dimention vector of parameters. To test the association between multiple phenotypes
and the variant is equivalent to test the null hypothesis :
under equation (2.1). We
under equation (2.1).
use the score test statistic given by Sha et al. (2011) to test :
The test statistic is
,
where

∑
̅

,

1

̅

(2.2)

̅ ∑

, ̅

∑

,

∑
,…,
and
for
1, … ,
. The test statistic
,
asymptotically follows a chi-square distribution with degrees of freedom.
When K is large, the score test may lose power due to the large degrees of freedom. To
overcome this problem, we combine the phenotypes to one variable by using a linear
∑
combination of phenotypes,
, , where w1 ,, wK are the weights. With the
∑
linear combination of phenotypes
, , the score test statistic in equation
(2.2) becomes
,…,

2

∑
∑
̅

̅
∑

.

(2.3)
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We propose to use the optimal weights proposed by Sha et al. (2012), that is,
∑
̅
∑

,

for

1,2, … , . Actually, the optimal weights

,…,

maximize

,

,…,
phenotypes

in equation (2.3). With this optimally weighted combination of
∑
, , the test statistic given in equation (1.3) becomes
,…,

2 ∙

∑
̅
∑

,
̅

(2.4)

∑
where
. From equation (2.2) to equation (2.4), we reduced the dimension
of the phenotypes from multivariate
1, … ,
to univariate
with optimal
, ,
weights
such that equation (1.4) is the maximum of equation (2.3). Since
,…,
are data-driven weights,
,…,
does not follow a chi-square distribution. We use a
permutation procedure to evaluate the p-value of
,…,
. In each permutation, we
̅
randomly shuffle the genotypes and keep the phenotypes unchanged. Since ∑
does not change under each permutation, the test statistic
,…,
is equivalent to
∑
̅

.

(2.5)

This test statistic T is our proposed test statistic to test the effect of the Weighted
Combination of multiple Phenotypes (WCmulP).
The WCmulP method can also be extended to incorporate covariates. Suppose that there
are covariates. Let Z i ,l denote the l th covariate of the i th individual. We define
covariate corresponding to the two alleles x2 i 1 and x2i of the
individual
, and z 2 i ,l , where z 2 i 1,l  z 2 i ,l  Z i ,l . We then adjust the phenotype value , for
the covariates by applying linear regressions. That is,
the
as

,

Let , denote the residuals of
effects in WCmulP by replacing
of WCmulP is defined as

,

,

,
,

⋯

,

,

,

,

.

in the linear regression. We incorporate the covariate
in equation (2.5) by , . With covariates, the statistic
|

,

,

.
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2.3 Comparison of Methods
We compare the power of the proposed WCmulP with that of the following methods:
Score (Score test): the test statistic of Score is given by equation (2.2).
OB (O’Brien’s method) (O’Brien, 1984): the test statistic of OB,
uni , is a linear
combination of univariate test statistics, and it is the most powerful test among a class of
test statistics that are linear combination of uni , where uni is the vector of the univariate
test statistics, Σ is the covariance matrix of uni , and
1,1 … ,1 is a 1’s vector with
length (the number of phenotypes).
MultiPhen (Joint model of Multiple Phenotypes) (O’Reilly et al., 2012): it uses the
proportional odds logistic regression to model the genotype data as ordinal response and
phenotypes as predictors. A likelihood ratio test is used to test the null hypothesis.
TATES (Trait-based Association Test that uses Extended Simes procedure) (van der Sluis
et al., 2013): it combines univariate p-values to acquire one phenotype-based p-value, while
correcting for correlations between phenotypes. The TATES p-value is given
by

, where

1, … ,

is the

sorted p-value in ascending order,

and
are the effective numbers of independent p-values of all phenotypes and
specified phenotypes, respectively. The effective numbers can be calculated from the
correlation matrix of p-values.
CCA (Canonical Correlation Analysis) (Ferreira and Purcell, 2009): it extracts the linear
combination of phenotypes that maximizes the correlations between linear combinations
of phenotypes and genotypes at the variant of interest. The test is based on Wilks’ lambda
and the corresponding F-approximation.
SHet (Test for Heterogeneous genetic effects) (Zhu et al., 2015): The test statistic of SHet,
, is based on
, which is the most powerful test statistic when the genetic effect is
homogeneous. Both
and
are quadratic combinations of the univariate test
statistics. The test statistic of

is

uni

uni

, where

is the

correlation matrix of uni ,
is a diagonal matrix of weights for the univariate test
statistics, and is a 1’s vector with length (number of phenotypes).
can be viewed
as the maximum of
’s satisfying different thresholds. More specifically, given a
threshold, only test statistics with absolute values that are greater than the threshold are
used, and are therefore partially used corresponding to the selected test statistics. The
p-values of
can be evaluated by simulation.
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2.4 Simulation Studies
Our simulations are similar to that of Wang et al. (2016). To evaluate the type I error rates
and powers of our method, we simulate genotype-phenotype data sets for unrelated
individuals with total
phenotypes according to a variety of simulation scenarios.
Specifically, genotype data at a genetic variant are simulated according to the minor allele
frequency (MAF) under the assumption of Hardy-Weinberg equilibrium. We generate K
phenotypes by the factor model

y   x  cγf  1  c2   ,

(2.6)

where y   y1 ,, yK  ; x is the genotype score at the variant of interest;    1 ,  ,  K 
T

is the vector of effect sizes of the genetic variant on the K phenotypes;
T
f   f1 , , f R  ~ MVN  0,   ,   1    I   A , R is the number of factors, A is a
matrix with elements of 1, I is the identity matrix, and  is the correlation between fi
and f j for

i  j ; γ is a K by R matrix; c is a constant number; and    1 ,,  K T is

a vector of residuals,  1 ,  ,  K are independent, and  k ~ N  0,1 for k  1,, K . Based
on equation (2.6), we consider the following six models.
Model 1: There is only one factor and genotype has impacts on all traits with the same
T
T
effect size. That is, R  1 ,     ,,   , and γ  1, ,1 .

Model 2: There are two factors and genotype has impacts on two factors with opposite
T


effects. That is, R  2 ,      ,,   ,  ,,   , and
,
, where
 


 
K 2
K 2


T



for i  1,2 , “
Di   1,

,1



 K2 

” indicates the block diagonal matrix.

Model 3: There are two factors and genotype has impacts on one factor. That is, R  2 ,
T



 , and
   0,  , 0, 

,
,




K 2



T

,



, where Di   1,

,1
for i  1,2 .



K
2



Model 4: There are four factors and genotype has impacts on one factor. That is, R  4 ,
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   0,, 0, 
,
,




K 4


i  1,,4 .

T

T

,

, and

,



, where Di  1,
,1




 K4 

,

for

Model 5: There are four factors and genotype has impacts on two factors. That is, R  4 ,
T

T




  0,,0, 
,
, 
 ,

,
,
  , and





K 4
K 4


for i  1,,4 .

,

,

,



, where Di  1,
,1




 K4 

Model 6: There are four factors and genotype has impacts on three factors. That is, R  4
T



2
2
2
K

,   0,,0,
 ,


,
,
 1,
 2,,
 ,   ,, 



K 4 1
K 4 1
K 4  1 4 
K 4
K 4



, and

T

,

,

,



, where Di  1,
for i  1,,4 .

,1



 K4 

In the six models, the within-factor correlation is and the between-factor correlation
is
. The structures of and cov | for different numbers of factors (
1, 2, and 4)
when the number of phenotypes is 8 are given in Table A.2.2.
We also generate phenotypes with covariates effects. We refer to Sha et al. (2012) and Sun
et
al.
(2016)
by
adding
two
covariates
in
equation
(2.6)
as

y   0.5z1  0.5z2  e   x  cγf  1  c2   , where z1 is a continuous random variable
generated from a standard normal distribution, z2 is a binary random variable taking
values of 0 and 1 with a probability of 0.5, and e is a K-dimensional vector with all
elements being 1’s. To evaluate type I error rates and powers, we consider
1,000 unrelated individuals,
0.3, and different numbers of phenotypes K  8,16 .
To evaluate the type I error rates of all methods, we generate all phenotypes independent
of genotypes by setting   0 . We evaluate type I error rates at significance levels
0.001 and 0.01 for all methods. To evaluate powers, we vary the values of  (withinfactor correlation c 2  0.5 and between-factor correlation  c 2  0.1 ) and vary the values
2

of within-factor correlation c (0.3,0.5,...,0.9) (between-factor correlation  c 2  0.1 and
0.1,).
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2.5 Simulation Results
To evaluate the type I error rates of WCmulP and other six methods, we consider different
numbers of phenotypes, different significance levels, and different numbers of factors. In
each simulation scenario, the p-values of WCmulP and SHet are estimated using 10,000
permutations, and the p-values of Score, MultiPhen, TATES, CCA and OB are estimated
using their asymptotic distributions. The type I error rates of the seven methods are
evaluated using 10,000 replicated samples. For 10,000 replicated samples, the 95%
confidence intervals (CIs) for type I error rates of nominal levels 0.001 and 0.01 are
0.00038, 0.00162 and 0.008, 0.012 , respectively. The estimated type I error rates of
WCmulP and other six methods are summarized in Table 2.1 (
8) and Table 2.2 (
16). From these tables, we can see that all estimated type I error rates of WCmulP are
within 95% CIs, which indicates that the proposed WCmulP is a valid test. The estimated
type I error rates of SHet, Score, MultiPhen, TATES, CCA and OB are not significantly
different from the nominal levels.
For power comparisons, we consider power as a function of genetic effect (Figures 2.12.2) and power as a function of within-factor correlation (Figures 2.3-2.4). In each of
the simulation scenario, the p-values of WCmulP and SHet are estimated using 1,000
permutations and the p-values of Score, MultiPhen, TATES, CCA and OB are estimated
using their asymptotic distributions. The powers of the seven methods are evaluated using
1,000 replicated samples at a significance level of 0.01.
Our simulation results show that:
1. As expected, the powers of all methods increase as the genetic effect
increases in each model (Figures 2.1-2.2).
2. WCmulP is either the most powerful test or comparable to the most powerful
tests in all six models (Figures 2.1-2.4).
3. As number of phenotypes increases from
8 to
16, WCmulP presents
more obvious ascendancy than other methods.
4. SHet, Score, MultiPhen, and CCA have similar performance in all six models;
we call these four tests as group 1.
5. OB is the most powerful test when the genetic effects are homogeneous (model
1). However, OB reduces power significantly when genetic effects are
heterogeneous, especially when opposite directions of the genetic effects exist
(models 2, 5-6) or when the genetic variant impacts only a small portion of
phenotypes (model 4). This phenomenon was also observed by Zhu et al.
(2015).
6. Power comparisons of TATES with tests in group 1 depend on the models. In
general, TATES is more powerful than tests in group 1 when the genetic variant
impacts on a portion of phenotypes (models 3 and 4).
increases, the powers of all
7. In general, as the within-factor correlation
methods decrease (Figures 2.3-2.4). TATES is relatively robust to because
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it essentially only depends on the phenotype that has the strongest association
with the genetic variant, as explained in Zhu et al. (2015).
We also considered using principal components (PCs) of the phenotypes instead of the
original phenotypes to do power comparisons and the results are given in Figures B.2.1B.2.4. We exclude PCs that explain less than 10-6 of the total variation. Using PCs of the
phenotypes, we observe that: (1) WCmulP, Score, MultiPhen, and CCA have very similar
powers in all six models (Figures B.2.1-B.2.4). We call these tests as group s1. The tests
in group s1 are either the most powerful tests or comparable to the most powerful one; (2)
SHet is less powerful than the tests in group s1; (3) OB is the least powerful method in all
six models because PCs likely have effects with different directions; (4) TATES becomes
the most powerful method when the genetic variant has effects on all phenotypes with the
same absolute value of effect sizes (models 1 and 2) because in this case, one of the PCs
may capture the most of association information.
We also compared the powers using a lower significance level 5×10-5 (Figure B.2.5).
Figure B.2.5 shows that the pattern of the power comparisons by using significance level
5×10-5 is similar to that by using significance level 0.01 (Figure 2.1).
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2.6 Real Data Analysis
Chronic obstructive pulmonary disease (COPD) refers to a group of diseases that cause
airflow blockage and breathing-related problems. The Genetic Epidemiology of COPD
Study (COPDGene) is a multicenter observational study designed to identify genetic
factors associated with COPD, to define and characterize disease-related phenotypes, and
to assess the association of disease-related phenotypes with the identified susceptibility
genes (Regan et al., 2010). 10,192 participants (including 6,784 non-Hispanic Whites
(NHW) and 3,408 African-Americans (AA)) are included in COPDGene. We selected 7
key quantitative COPD-related phenotypes and 4 covariates that are the same as those in
Liang et al. (2016). The detailed description of these 7 phenotypes is in Table 2.3, and their
correlation structure is given in Figure B.2.6. The four covariates include Body Mass Index,
Age, Pack-Years (one pack-year is defined as smoking one pack per day for one year), and
gender. A set of 5,430 NHW across 630,860 SNPs were used in the analysis after excluding
subjects with missing data in any of the 11 variables.
We apply WCmulP and other six methods to both original 7 phenotypes (Table 2.4) and
the principal components (PCs) of the phenotypes (Table A.2.1). PCs that explain less than
10-6 of the total variation are excluded. In this way, one PC is excluded and there are 6 PCs
left. Using the first few PCs is also a dimension reduction method. Thus, using PCs of the
phenotypes, WCmulP uses two dimension reduction methods: using the first few PCs and
the weighted combination of those PCs. To identify SNPs significantly associated with the
7 COPD-related phenotypes and the top 6 PCs of the phenotypes, we use the genome-wide
significance threshold of 5 10 . There are total 16 SNPs that are significant under at
least one method (Table 2.4 and Table A.2.1). Those 16 SNPs have been reported being
associated with the COPD-related phenotypes by previous studies (Pillai et al., 2009; Wilk
et al., 2009; Wilk et al., 2012; Cho et al., 2010; Cho et al., 2010; 2012; 2014; Hancock et
al., 2010; Young et al., 2010; Li et al., 2011; Zhang et al., 2011; Cui et al., 2014; Zhu et
al., 2014; Lutz et al., 2015; Lee et al., 2015). From Table 2.4, we can see that MultiPhen
identified the largest number of SNPs, 14 SNPs; WCmulP, SHet, Score, and CCA
identified 13 SNPs; TATES identified 9 SNPs; and OB didn’t identify any SNPs, that’s
likely because the true genetic effects of each SNP are heterogeneous for all phenotypes.
From Table A.2.1, we can see that using PCs of the phenotypes, WCmulP identified all of
the 16 SNPs; MultiPhen identified 15 SNPs; SHet, Score, and CCA identified 13 SNPs;
TATES identified 4 SNPs; and OB identified 3 SNPs. In summary, the number of SNPs
identified by WCmulP is comparable to the largest number of SNPs identified by other
tests; and using PCs of phenotypes, WCmulP is the only method that identified all 16 SNPs.
The results of the real data analysis are consistent with our simulation results.
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2.7 Discussion
In this article, we developed WCmulP to perform multivariate analysis of multiple
phenotypes in association studies based on the following reasons: (1) complex diseases are
usually measured by multiple correlated phenotypes in genetic association studies; and (2)
there is increasing evidence showing that studying multiple correlated phenotypes jointly
may increase powers for detecting genetic variants that are associated with complex
diseases. Our results show that WCmulP has correct type I error rates and is either the most
powerful test or comparable to the most powerful tests among the seven tests we
considered. None of the other methods showed consistent good performances under the
simulation scenarios. OB is the most powerful test when the genetic effects are
homogeneous, while it loses power dramatically when genetic effects are heterogeneous;
especially when opposite directions of the genetic effects exist. SHet, Score, MultiPhen,
and CCA have similar powers and they are less powerful than WCmulP in most scenarios.
TATES is more powerful only when the genetic variant affects a portion of phenotypes. In
addition, in the real data analysis, WCmulP identified 13 (out of 16) significant SNPs, 1
SNP less than the largest number of identified SNPs; using PCs of phenotypes, WCmulP
is the only method that identified all 16 SNPs. The real data analysis results show that
WCmulP has excellent performance in identifying SNPs associated with complex disease
with multiple correlated phenotypes such as COPD.
In the context of association studies, it is important to correct for population stratification
(PS). PS refers to allele frequency differences between populations unrelated to the
outcome of interest, but due to systematic ancestry differences. PS can cause seriously
confounded associations if not adjusted properly (Knowler et al., 1988; Lander and Schork,
1994). The principal component analysis (PCA) method (Chen et al., 2003; Zhang et al.,
2003; Zhu et al., 2002; Price et al., 2006; Bauchet et al., 2007) and linear mixed model
(LMM) approach (Kang et al., 2010; Zhang et al., 2010; Hoffman, 2013) have been used
to adjust for population stratification. There are also other methods such as
multidimensional scaling (MDS) (Li and Yu, 2008), the robust PCA based on resampling
by half means (RPCA-RHM) (Liu et al., 2013), and the robust PCA based on the projection
pursuit (RPCA-PP) (Liu et al., 2013), which are extension methods of the PCA approach.
PCA identifies several top principal components of the genotype data matrix and uses them
as covariates in the association analysis. We propose to use PCA to control for PS in our
proposed method when samples from different populations are involved. However, the
performance needs further investigations.
One disadvantage of WCmulP is that the test statistic does not have an asymptotic
distribution and a permutation procedure is needed to calculate its p-value, which is time
consuming compared to the methods whose test statistics have asymptotic distributions.
The running time of WCmulP with 1,000 permutations on a data set with 5,000 individuals
and 20 phenotypes on a laptop with 4 Intel(R) Cores(TM) i7-4790 CPU @ 3.6GHz and 4
GB memory is no more than 0.15s. To perform GWAS, we can first select genetic variants
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that show evidence of association based on a small number of permutations (e.g. 1,000),
and then a large number of permutations are used to test the selected significant genetic
variants (Wang et al., 2016). Furthermore, WCmulP cannot be used for rare variant
association studies, although recent studies have shown that complex diseases are caused
by both common and rare variants (Kang et al., 2010; Bodmer and Bonilla, 2008; Pritchard
and Cox, 2002; Teer and Mullikin, 2010; Walsh and King, 2007). How to extend WCmulP
to rare variant association studies is our future work.
In our simulation studies, the numbers of phenotypes varied from 8 to 16 and the methods
rely on all observations having fully observed phenotypes. However, in real data analysis,
as the number of phenotypes increases the chance that missing at least one observation
increases exponentially, especially in epidemiological and clinical research (Ali et al.,
2011; Dahl et al., 2016). There are several approaches to handle missing phenotypes:
deletion-based methods, simple replacement methods, and imputation methods (Ali et al.,
2011). The most commonly used method for dealing with missing data is deletion-based
method, in which observations with missing values are removed from the analysis (Ali et
al., 2011). However, removal of observations with missing values will reduce sample size,
thus resulting in power losses (Dahl et al., 2016). The simple replacement methods replace
the missing values with plausible values for the variable with missing values, such as the
sample mean (van der Sluis et al., 2013; Ali et al., 2011). It is a simple, unconditional
method that does not depend on other variables. However, mean substitution approach may
result in biased estimates where data are not missing completely at random (Ali et al.,
2011). Imputation is a more sophisticated approach that fills in missing values with
predicted values using model-based methods or conditional imputation, including multiple
imputation (MI), multivariate normal imputation (MVNI), and fully conditional
specification (FCS) (Ali et al., 2011; De Silva et al., 2017; Schafer, 1997; Carlin, 2015;
Raghunathan et al., 2001; Van Buuren et al., 2006; Carpenter and Kenward, 2012). In MI,
the incomplete dataset is generated multiple times and missing values are replaced by
values drawn from a posterior distribution according to a suitable imputation model that
utilizes the rest of the data (Ali et al., 2011; De Silva et al., 2017). MVNI fits a joint
imputation model to all the variables containing missing values under the assumption that
the variables follow a multivariate normal distribution (Schafer, 1997; Carlin, 2015). For
each variable with missing values, FCS fits separate univariate regression models and
iteratively cycles through the univariate regression models (Raghunathan et al., 2001; Van
Buuren et al., 2006; Carpenter and Kenward, 2012). In our real data analysis, we removed
1354 observations with missing either phenotypes or covariates from 6784 samples. An
alternative approach is to use mean substitution or imputation approaches to fill in the
missing values.
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2.8 Tables and Figures
Table 2.1. Estimated type I error rates for the seven methods under three simulation
settings. The number of phenotypes is
8,
0.5,
0.1, and
0.3. The
p-values of WCmulp and SHet are evaluated using 10,000 permutations. The type I error
rate of all of the seven methods is evaluated using 10,000 replicated samples at a
significance level of .
Type I error rates
1
Methods

0.001

2
0.01

0.001

4
0.01

0.001

0.01

WCmulP

0.0008

0.0097

0.0011

0.0091

0.0011

0.0104

SHet

0.0008

0.0106

0.0009

0.0093

0.0008

0.0104

Score

0.0006

0.0102

0.0008

0.0103

0.0004

0.0105

MultiPhen

0.0011

0.0106

0.0011

0.0105

0.0005

0.0107

TATES

0.0012

0.0094

0.0007

0.0121

0.0004

0.0106

CCA

0.0008

0.0107

0.0010

0.0099

0.0008

0.0107

0.0007

0.0095

0.0016

0.0092

0.0013

0.0105

OB

Note:

is the number of factors.
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Table 2.2. Estimated type I error rates for the seven methods under three simulation
settings. The number of phenotypes is
16 ,
0.5 ,
0.1 , and
0.3 .
The p-values of WCmulp and SHet are evaluated using 10,000 permutations. The type I
error rate of all of the seven methods is evaluated using 10,000 replicated samples at a
significance level of .
Type I error rates
1
Methods

0.001

2
0.01

0.001

4
0.01

0.001

0.01

WCmulP

0.0011

0.0089

0.0006

0.0094

0.0008

0.0098

SHet

0.0009

0.0098

0.0009

0.0126

0.0008

0.0088

Score

0.0010

0.0096

0.0011

0.0098

0.0010

0.0086

MultiPhen

0.0011

0.0096

0.0011

0.0121

0.0013

0.0103

TATES

0.0013

0.0110

0.0012

0.0102

0.0008

0.0104

CCA

0.0012

0.0097

0.0009

0.0111

0.0011

0.0089

OB

0.0011

0.0085

0.0006

0.0092

0.0007

0.0097
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Table 2.3. Description of COPD-related phenotypes

Phenotypes

Descriptions

Gas Trapping (GasTrap)

Air trapping at -856 Hounsfield units (HU)
on expiratory chest CT scan

Exacerbation Frequency (ExacerFreq)

Number of COPD exacerbations during the
year before study enrollment

Emphysema (Emph)

% Emphysema at -950 HU

Airway Wall Area (Pi10)

Square root of the wall area of a
hypothetical 10 mm internal perimeter
airway

Emphysema Distribution (EmphDist)

Log ratio of emphysema at -950 HU in the
upper 1/3 of lung fields compared to the
lower 1/3 of lung fields

Six Minute Walk Distance (6MWD)

Measure of exercise capacity

FEV1

Observed FEV1 (liters)/predicted FEV1
(liters), with predicted values from
Hankinson reference equations
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Table 2.4. Significant SNPs and the corresponding p-values in the analysis of COPDGene.
The p-values of WCmulP are evaluated using 10 permutations; the p-values of SHet are
evaluated using 10 permutations. The p-values of Score, MultiPhen, CCA, TATES, and
OB are evaluated using asymptotic distributions. The grayed-out p-values indicate the pvalues 5 10 .
Chr

Variant identifier

WCmulP

SHet

Score

MultiPhen

CCA

TATES

OB

4

rs1512282

0

1.0E-08

1.90E-09

1.03E-09

1.69E-09

5.77E-09

0.339

4

rs1032297

0

0

5.55E-14

7.69E-14

6.52E-14

6.22E-13

0.452

4

rs1489759

0

0

1.11E-16

1.22E-16

1.11E-16

2.52E-16

0.483

4

rs1980057

0

0

1.11E-16

8.14E-17

0

9.35E-17

0.411

4

rs7655625

0

0

1.11E-16

9.13E-17

0

1.64E-16

0.478

15

rs16969968

0

0

1.91E-11

7.84E-12

1.32E-11

2.98E-08

0.986

15

rs1051730

1.00E-08

0

2.05E-11

8.16E-12

1.41E-11

2.63E-08

0.992

15

rs12914385

0

0

1.78E-12

1.48E-12

1.76E-12

5.14E-10

0.999

15

rs8040868

0

0

2.21E-12

2.59E-12

2.74E-12

2.40E-09

0.768

15

rs951266

2.00E-08

0

2.42E-11

1.02E-11

1.77E-11

5.17E-08

0.956

15

rs8034191

4.00E-08

1.0E-08

2.95E-10

7.74E-11

2.14E-10

1.02E-07

0.868

15

rs2036527

4.00E-08

1.0E-08

5.58E-10

1.77E-10

3.99E-10

1.56E-07

0.880

15

rs931794

4.80E-08

3.0E-08

3.13E-10

9.09E-11

2.35E-10

1.18E-07

0.913

15

rs2568494

7.18E-06

1.93E-06

1.22E-07

4.23E-08

1.05E-07

2.88E-05

0.269

15

rs17483721

8.12E-06

2.29E-06

2.26E-07

9.87E-08

2.11E-07

3.57E-05

0.308

15

rs17483929

8.15E-06

2.13E-06

1.65E-07

6.53E-08

1.50E-07

2.82E-05

0.347
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Figure 2.1. Power comparisons of the seven methods as a function of for the six models.
The total number of phenotypes is
8,
0.5,
0.1, and
0.3. The pvalues of WCmulP and SHet are evaluated using 1,000 permutations. The power of all of
the seven methods is evaluated using 1,000 replicated samples at a significance level of
0.01.
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Figure 2.2. Power comparisons of the seven methods as a function of for the six models.
The total number of phenotypes is
16,
0.5,
0.1, and
0.3. The pvalues of WCmulP and SHet are evaluated using 1,000 permutations. The power of all of
the seven methods is evaluated using 1,000 replicated samples at a significance level of
0.01.
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Figure 2.3. Power comparisons of the seven methods as a function of for the six models.
The total number of phenotypes is
8,
0.1,
0.1, and
0.3. The pvalues of WCmulP and SHet are evaluated using 1,000 permutations, the p-values of other
methods are evaluated using asymptotic distribution. The power of all of the seven methods
is evaluated using 1,000 replicated samples at a significance level of 0.01.
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Figure 2.4. Power comparisons of the seven methods as a function of for the six models.
The total number of phenotypes is
16,
0.1,
0.1, and
0.3. The pvalues of WCmulP and SHet are evaluated using 1,000 permutations, the p-values of other
methods are evaluated using asymptotic distribution. The power of all of the seven methods
is evaluated using 1,000 replicated samples at a significance level of 0.01.
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3 Chapter 3
PheCLC: a Novel Statistical Method for Phenome-Wide Association Studies
Over the last decade, genome-wide association studies (GWAS) have been widely
performed to identify genetic associations for many complex diseases. Typically, GWAS
use a phenotype-to-genotype strategy, starting with a particular phenotype that is
associated with genetic variants across the genome, and over 1,000 GWAS have been
published linking thousands of statistically significant genetic variants to hundreds of
human diseases and traits. A common limitation of GWAS is that they focus on only a
single phenotype or a small set of phenotypes at a time. As a complement to GWAS,
phenome-wide association studies (PheWAS) use a genotype-to-phenotype approach,
beginning with a genotype to test for associations over a broad range of phenotypes.
PheWAS were first demonstrated with electronic health record (EHR) data in 2010 and
have already demonstrated their capacity to discover genetic association related to a wide
range of diseases. In this article, we derived a novel and powerful multivariate method,
which we referred as PheCLC, to test the association between a genetic variant with large
numbers of phenotypes. Suppose that there is a certain number of phenotypic categories
containing different phenotypes. PheCLC first calculates the p-values for testing the variant
of interest and the phenotypes within each phenotypic category using a clustering linear
combination method recently proposed by our group. Then, it combines the p-values
obtained from the first step using the method similar to adaptive Fisher’s combination
method (Liang et al., 2016). We perform extensive simulation studies to compare the
PheCLC method with other existing methods. The results show that our proposed PheCLC
method controls the type I error rates very well and has outstanding performance over other
methods.

3.1 Introduction
Over the last decade, as the completion of the Human Genome Project (Venter et al., 2001;
Lander et al., 2001) and the HapMap Project (Frazer et al., 2007; International HapMap
Consortium), our understanding of human genetic variation in the genome and its
connection to human health were dramatically accelerated. As a result, genome-wide
association studies (GWAS) emerged and have been widely used to identify genes or
genetic variants that are associated with a single or a small number of human traits and
diseases (Bush and Moore, 2012; Witte, 2010). By 2011, the US National Human Genome
Research Institute (NHGRI) and the European Bioinformatics Institute (EMBL-EBI)
published the GWAS Catalog (http://www.ebi.ac.uk/gwas/ ) highlighting a review of
GWAS-identified variants, traits and studies (Hindorff et al., 2009). This review
demonstrated that almost 5% of single nucleotide polymorphisms (SNPs) and almost 17%
of genes are associated with more than one human traits (Sivakumaran et al., 2011). By
2013, over 1000 GWAS had been published linking up to 4000 statistically significant
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genetic variants to over 500 human traits and diseases (Hebbring, 2014). In general, GWAS
use a phenotype-to-genotype strategy, beginning with a single disease or a small number
of diseases, to evaluate the associations between the pre-defined disease or diseases and
hundreds of thousands, to over a million, genetic variants across the genome and to identify
the significant genetic associations (Hebbring, 2014; Pendergrass et al., 2013; Denny et al.,
2016). However, GWAS have several limitations. Frist, a general accepted significance
threshold (5 10 ) is commonly used in GWAS and the genetic variant with p-value
which is less than this threshold is considered as significant (McCarthy et al., 2008; Risch
and Merikangas, 1996). However, reaching this threshold by GWAS can be a challenge
due to the burden of large-scale multiple testing. Second, the vast majority (more than 90%
as reported by Paul et al., 2014) of significant SNPs are located in the intergenic regions
(IGR) which are a subset of noncoding DNA. Identifying and interpreting their associations
with human diseases is a major challenge (Hebbring, 2014). Third, GWAS SNPs are
mainly tag SNPs (i.e. SNPs that have strong linkage disequilibrium (LD) with a causal
variant) for common variants (Hindorff et al., 2009). Fourth, GWAS are examining the
association with genetic variants with a limited number of traits and phenotypes
(Pendergrass et al., 2012; Pendergrass et al., 2013; Bush et al., 2016; Denny et al., 2016).
Therefore, most GWAS fail to identify clinically or biologically significant associations
(Hebbring, 2014).
As an alternative approach to GWAS, phenome-wide association studies (PheWAS) is
rapidly used to evaluate the impact of one or many genetic variants on a very broad range
of phenotypes – the phenome (Pendergrass et al., 2012; Pendergrass et al., 2013; Hebbring,
2014). PheWAS came into view partly due to the availability of dense electronic health
record (EHR) data, which is the most frequently used phenome. In 2010, PheWAS was
first performed as a method with EHR data and published in Bioinformatics (Denney et al.,
2010). Since then, more than half of PheWAS investigations have been demonstrated with
EHR data (Denny et al., 2016). However, EHR-based phenotype data are generally
collected for clinical use and may depict limited racial diversity (McCarty et al., 2011;
Denny et al., 2010). Published PheWAS have been mainly implemented with the Electronic
Medical Records and Genomics (Emerge) Network and Population Architecture using
Genomics and Epidemiology (PAGE) I Network (Bush et al., 2016). Even though,
PheWAS approach is still in an early stage, it has successfully displayed its capability of
exploring the association between genetic variants and an extensive range of phenotypes.
In the mechanics of conducting genetic association tests, current PheWAS are similar to
the widely used GWAS, but from an inverse perspective. PheWAS use a genotype-tophenotype strategy, starting with a genetic variant of interest to test for associations across
the so-called phenome (Hebbring, 2014). Flipping the direction of inference in PheWAS,
compared with GWAS, has several motivations. First, genetic variants can be
systematically analyzed for their effects on clinical traits and diseases (Bush et al., 2016).
Second, genetic variants have long been recognized as factors that influence human
diseases and traits, and they may depend on environmental exposures and life stages (Ober
and Vercelli, 2011), both of which can be involved in complete phenome. Third, many
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conditions have known comorbidities and have multiple genetic factors that contribute to
their etiology. Available methods for PheWAS include univariate association test, which
conducts a single test of association between the genetic variant of interest and each
phenotype at a time, and multivariate methods, which test the genetic variant and a large
number of phenotypes jointly. Many GWAS reported that the multivariate tests are more
powerful than the univariate tests. Here, we review the commonly adopted multivariate
methods for PheWAS: proportional odds logistic regression for joint model of multiple
phenotypes (MultiPhen) (O’Reilly et al., 2012), which regresses the genetic variant on
multiple phenotypes, fits the proportional odds regression model and uses a likelihood ratio
test to obtain the p-value; the Trait-based Association Test that uses Extended Simes
procedure (TATES) (van der Sluis et al., 2013), in which univariate p-values are combined
to acquire one phenotype-based p-value, while correcting for correlations between
phenotypes; the Principal Component of Heritability association test (PCH) (Klei et al.,
2008), which reduces the phenotypes to a single trait that has a higher heritability than any
other linear combination of the phenotypes; canonical correlation analysis (CCA) (Ferreira
and Purcell, 2009), which extracts the linear combination of phenotypes that explain the
largest possible amount of the covariation between the genetic variant and all phenotypes;
multivariate analysis of variance (MANOVA); and BIMBAM, which is a Bayesian model
comparison and model averaging for multivariate regression (Stephens, 2013). Bush et al.
(2016) compared the performance of those methods and reported that not a single approach
performs best under all scenarios. Zhu et al. (2015) also compared most of the above
methods (MultiPhen, TATES, PCH, CCA, and MANOVA) and pointed out that over all
the simulation scenarios, MultiPhen, PCH, CCA, and MANOVA have very similar power
when a small number of phenotypes are considered ( 20).
In this article, we propose a novel and powerful multivariate approach that we refer to as
PheCLC (Phenome-wide association study that uses Clustering Linear Combination
method). This method can deal with more than one thousand correlated or uncorrelated
phenotypes with over two thousand individuals. We suppose that the whole phenome can
be classified into numerous phenotypic categories and each category contains a certain
number of phenotypes. PheCLC is a two-step approach. In the first step, we apply the
clustering linear combination (CLC) method within each phenotypic category and derive a
CLC p-value for testing the genetic variant of interest with all phenotypes in that category.
The second step then combines all CLC p-values obtained from the first step by using
Adaptive Fisher’s Combination (AFC) method (Liang et al., 2016). In the simulation
studies, we use the factor model (Wang et al., 2016) to generate thousands of phenotypes
and evaluate the performance of our proposed PheCLC method, the results show that
PheCLC has correct type I error rates and outperforms other methods that we compared
with.
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3.2 Methods
In our analyses, we consider a sample with n
2,000 unrelated individuals, indexed
by
1,2, … , . Each individual has K
1,000 phenotypes in total and suppose
these K phenotypes are from M phenotypic categories in which the effects of genetic
variant are different. Suppose that there are Km phenotypes in the m th category,
1,2, … , and K1  KM  K . Let yimk denote the k th phenotype in the m th
where
category of the ith individual and xi denote the genotype at the variant of interest for the
i th individual. We can also incorporate covariates into the analyses. Suppose that there are
th
p covariates, zi1 ,, zip , for the i individual, we adjust both the genotypes and phenotype
values for the covariates using the method applied by Price et al. (2006) and Sha et al.
(2012). That is, we regress both genotypes and phenotypes on the covariates through the
following two linear models
yimk   0 mk  1mk zi1  ...   pmk zip   imk and xi   0   1 zi1  ...   p zip   i .

For simplification, in what follows, we assume that there are no covariates. We then use
score statistics to test for association between the k th phenotype in the m th category and
0
 m1 k xi . The
the variant of interest under the generalized linear model g ( E ( yimk | xi ))  mk
score test statistic, Tmk , is given by
Tmk  U mk

Vmk ,

where Umk  i1 ( yimk  ymk )( xi  x ) and Vmk  i1 ( yimk  ymk )2 i1 ( xi  x )2 n . Under the
n

n

n

null hypothesis that there is no association between the genetic variant and the k th
phenotype in the m th category (i.e.
0), Tmk asymptotically follows standard normal
such score test
distribution. Following these univariate association tests, we obtained
statistics in the
category. Next, we introduce the clustering linear combination (CLC)
theorem and then apply CLC method to define an overall test statistic by combining the
univariate test statistics in each category.
,…,
∼
Theorem of Clustering Linear Combination: we assume that
,…,
. Suppose , … , can be divided into clusters. That
, Σ , where
1 ,…, 1
,1
1, … ,1 , and
⋯
. If the hierarchical
is,
clustering method can correctly cluster , the most powerful test among all tests in the
form
Σ
for an arbitrary
matrix is given by Clustering Linear
Combinations (CLC) test with statistic
Σ
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Σ

where

1 ,…,1

and

.

For the m th category, we apply CLC method to combine
,
,…,
and obtain one
CLC test statistic. Let us say that we calculate
(e.g.,
10 ) CLC test statistics,
CLC1,, CLCL0 , in the
category. We then calculate the p-values of CLC1,, CLCL0 ,
pm1,, pmL0 , and take the minimum value of these p-values, denoted pm  min1lL0 pml
p1 ,, p M 

p   p

M 
be order statistics of p1,, pM such that 1
. For any
c ,, cL   1,2,,10
predefined integer L and cut points 1  c1    cL  M (  1
), we define
the summation of negative log p m  at cut point cl as

1, … ,

. Let

cl

wl   log p m , l  1,, L .
m1

Let Pl denote the p-value of wl . Then, our proposed test statistic of PheCLC for testing the
association between the genetic variant and all phenotypes is given by

T  min1lL Pl .
To calculate the p-value of , we borrow the permutation procedure in Liang et al. (2016)
and state this procedure as follows.
Step 1. In each permutation, we randomly shuffle the genotypes and recalculate
,…,
and , … , . Suppose that we perform times of permutations. Let
(
0,1, … , ) denote the value of
0 represents the original data.
Step 2. We transfer

to

min

:

, ,…,

. Then, the p-value of
#

permuted data, where

by
#

Step 3. Let

based on the

:

, ,…,

.
is given by

.

As shown in Appendix of (Liang et al., 2016), the null distributions of , ,…, and thus
of do not depend on the genetic variant being tested. Thus, the permutation procedure
described above to generate an empirical null distribution of needs to be done only once
for many genetic variants.
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3.3 Simulations
To evaluate the type I error rates and powers of our proposed method, we generate
genotypes according to minor allele frequency (MAF) and assume Hardy Weinberg
Equilibrium. Then, we generate K phenotypes by the factor model (Wang et al., 2016)

y   x  cγf  1  c2   ,

(3.1)

where y   y1 ,, yK  ; x is the genotype score at the variant of interest;    1 , , K 
T

is the vector of effect sizes of the genetic variant on the K traits;
T
f   f1 ,, f M  ~ MVN  0,   ,   1    I   A , A is a matrix with elements of 1, I
is the identity matrix, and  is the correlation between categories; γ is a K by M
matrix; c is a constant number; and    1 ,,  K  is a vector of residuals, and  1 ,  ,  K
T

are independent, and  k ~ N  0,1 for k  1,, K .
Based on equation (3.1), we consider six models:
Model 1: There are M  100 categories and genotypes impact on one category. Let k 





T T
M

. That is,    ,, 

i  1,, M are

T
1

K
M

T



,1
, and γ  diag  D1 ,, DM  , where Di  1,

 k 

k dimensional vectors;

and iT for

1    M 1  0 and M  2  1,, k  .
k 1

Model 2: There are M  100 categories and genotypes impact on two categories. Let
K
. That is,
k
M

    ,, 
T
1



T T
M

T



,1
, and γ  diag  D1 ,, DM  , where Di  1,

 k 

and

iT for i  1,, M are k dimensional vectors; 1    M 2  0 , M 1  2  1, , k  , and
k 1









M    1,
1,
,
,1, 
1  .




k /2

k /2

Model 3: There are M  100 categories and genotypes impact on five categories. Let
K
. That is,
k
M

    ,, 
T
1



T T
M

T




,1
, and γ  diag  D1 ,, DM  , where Di  1,


 k 

and
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iT for i  1,, M are k dimensional vectors; 1    M 5  0 , M 4  2  1, , k  ,
k 1

 M 3  



  1,




,1,
1,
,
1

  , M 1   1,,1 , and M   1,,1 .
 
k /2
 k /2


2
1, , k  , M 2
k 1

Model 4: There are M  50 categories and genotypes impact on one category. Let k 





T T
M

That is,    ,, 
T
1

i  1,, M are

T



, and γ  diag  D1 ,, DM  , where Di  1,

,1


 k 

k dimensional vectors;

and iT for

1    M 1  0 and M  2  1,, k  .
k 1

Model 5: There are M  50 categories and genotypes impact on two categories. Let k 



. That is,    ,, 

i  1,, M are






T T
M

T
1

K
.
M

K
M

T




,1
, and γ  diag  D1 ,, DM  , where Di  1,


 k 

and iT for

2
dimensional vectors; 1    M 2  0 , M 1 
1, , k  , and

k

k 1
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1,
,
,1, 
1  .




k /2

k /2

Model 6: There are M  50 categories and genotypes impact on five categories. Let k 



. That is,    ,, 

i  1,, M are
 M 3  



T T
M

T
1

k

T




,1
, and γ  diag  D1 ,, DM  , where Di  1,


 k 

dimensional vectors; 1    M 5  0 ,

K
M

M  4 

and iT for

2
1, , k  ,
k 1



2
1,
,
,1, 
1 , M 1   1,,1 , and M   1,,1 .
1, , k  , M 2   1,




k 1
k /2
 k /2


To evaluate type I error rates of the proposed method, we let   0 . To evaluate powers,
we let   0 . In the simulation studies for evaluation of type I error rates and powers, we
1000,
2000, MAF = 0.3, c 2  0.5 and   0.2 .
set
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3.4 Results
To evaluate the type I error rats of PheCLC and other three methods, we consider different
numbers of categories. In each simulation scenario, the p-values of the proposed PheCLC
are estimated using 200 permutations, and the p-values of TATES, MANOVA and OB are
estimated using their asymptotic distributions. The type I error rates of all of the four
methods are evaluated using 1,000 replicates. For 1,000 replicates, the 95% confidence
intervals (CIs) for type I error rates of nominal levels 0.05 is (0.036, 0.063). The estimated
type I error rates of PheCLC and other three methods are summarized in Table 3.1. Wellcontrolled type I error rates were observed for PheCLC, TATES, MANOVA and OB in all
scenarios. Namely, the proposed PheCLC is proved to be a valid method.
To compare the powers of PheCLC with TATES, MANOVA and OB, we consider
different sample sizes, different numbers of phenotypes for all six models. The power of
the four methods at
0.05 is compared in Figure 3.1. We summarize the power
comparison results as follows.
1. PheCLC method outperformed TATAS, MANOVA and OB consistently in almost
all scenarios.
2. OB is the most powerful test among a class of tests with linear combination of
univariate test statistics being the overall test statistic when the genetic effects are
equal to each other (Yang et al., 2010). While in all of the six scenarios we
considered, both zero and nonzero values were assigned to the genetic effects,
which explains why the powers of OB are very low.
3. When genotypes have effects on more than two categories, the powers of PheCLC
are more than double that of TATES.
In most scenarios, MANOVA is more powerful than TATES, and its powers are at least
40% lower than that of PheCLC.
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3.5 Discussion
Over the last decade, GWAS have identified thousands of genetic variants that are
associated with human diseases and traits (Pendergrass et al., 2012; Pendergrass et al.,
2013; Hebbring, 2014; Bush et al., 2016). Unfortunately, most GWAS have a limitation
that they only focus on a pre-defined and a very limited number of phenotypes, as a result,
they fail to identify clinically significant associations in which large numbers of
phenotypes are involved (Pendergrass et al., 2012; Pendergrass et al., 2013; Denny et al.,
2016; Bush et al., 2016). As a complementary approach to GWAS, PheWAS can examine
the associations between genetic variants and a broad set of phenotypes and have
demonstrated to be effective in identifying significant variants (Hebbring, 2014;
Pendergrass and Ritchie, 2015; Pendergrass et al., 2015). In 2010, the first PheWAS was
published in Bioinformatics and it was a proof-of-concept (PoC) study that was not
designed to reveal new discoveries but to verify known GWAS-significant associations
and to validate the approach (Denny et al., 2010; Denny et al., 2011; Hebbring et al., 2013;
Liao et al., 2013; Pendergrass et al., 2013; Ritchie et al., 2013; Shameer et al., 2014; Bush
et al., 2016). Unlike GWAS that have been widely used for nearly a decade, PheWAS
approach is still in its infancy. Even so, they have already demonstrated their potentiality
to identify important genetic associations. PheWAS can be used to explore pleiotropy of
genetic variants in a broad spectrum of phenotypes, discover interrelationships between
phenotypes, and characterize the genetic architecture of many complex traits (Pendergrass
et al., 2012).
However, the PheWAS approaches have presented several challenges (Pendergrass et al.,
2012; Pendergrass et al., 2013; Hebbring 2014; Denny et al., 2016; Bush et al., 2016). The
biggest challenge of PheWAS is interpretations. For example, when there exists a
significant association between a genetic variant and multiple phenotypes, multiple
possible interpretations must be taken into consideration, such as true pleiotropy, false
phenotype distinction because of mis-characterization of the true phenotype, and
confounded phenotype relationships (Bush et al., 2016). Furthermore, the phenome is not
universally defined and PheWAS have been limited by how well the human phenome can
be defined (Hebbring, 2014). The International Classification of Disease (ICD) codes are
an internationally recognized, standardized coding system used to define disease status and
the two widely used versions are the ninth and tenth (ICD9/10) (Denny et al., 2010;
Hebbring, 2014). Unfortunately, not every ICD code is equal (McCarty et al., 2007), and
it’s infeasible to manually assess the validity of the whole phenome for all patients. Second,
like GWAS, PheWAS are hypothesis-generating approaches that are challenged by
multiple hypotheses (Hebbring, 2014). However, unlike GWAS in which a significance
threshold 5.0 10 is commonly used, a generally accepted threshold has not emerged
due to the variations in the number of phenotypes and genotypic variants in PheWAS (Bush
et al., 2016). One way to correct for multiple testing is Bonferroni correction; however it
may not be an appropriate comparison adjustment due to the non-independence of the
phenotypes as well as the variants (Hebbring, 2014; Verma et al., 2016). In addition,
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differences across populations may affect the ability to validate findings (Hebbring, 2014).
For example, it’s likely to see different results from a population with European ancestry
compared with a population with African ancestry due to significant differences in the
linkage disequilibrium structure and allele frequencies between the two populations
(Hebbring, 2014).
The PheWAS concept is not new, but it was not developed as a method until very recently
due to the limited availability of cohorts with multiple phenotypes (Bush et al., 2016).
Examples of available tests for PheWAS include MultiPhen (O’Reilly et al., 2012), PCH
(Klei et al., 2008), TATES (van der Sluis et al., 2013), CCA (Ferreira and Purcell, 2009),
MANOVA, and BIMBAM (Stephens, 2013). In this article, we proposed PheCLC to test
the association between a genetic variant and a wide spectrum of phenotypes. PheCLC
takes into account the possibility that phenotypes are from different phenotypic categories,
which is common in PheWAS due to the very large number of phenotypes, and conducts
genetic association tests in each category. Then, the p-values obtained from all categories
are combined using AFC method (Liang et al., 2016) in order to derive the PheCLC pvalue. Even though PheCLC has already demonstrated its validity and capacity in the
simulation studies, there are still some improvements in this method. Bush et al. (2016)
pointed out the necessity of using meta-analysis for PheWAS, and how to apply PheCLC
to meta-analysis becomes one of our future projects. In addition, we will extend PheCLC
approach to perform pathway-based analysis. As Hebbring (2014) reported that, the
pathways may play an essential role in many disease aetiologies.
To summarize, PheCLC has well-controlled type I error rates and is more powerful than
the currently available methods for PheWAS in most scenarios that we studied. PheCLC
allows researchers to test genetic associations for a large number of phenotypes that are
from different phenotypic categories.
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3.6 Tables and Figures
Table 3.1. Estimated type I error rates for the four methods with different number of
categories. The sample size is 2000, the total number of phenotypes is =1000, rho is 0.2,
=0.5 and MAF is 0.3. The type I error rate is evaluated using 1,000 replicated samples
at a significance level of 0.05.
Type I error rates
Methods
100

50

PheCLC

0.053

0.058

TATES

0.058

0.038

MANOVA

0.040

0.058

OB

0.038

0.040

50

Figure 3.1. Power comparisons of the four methods as a function of beta for the six models.
1000, MAF is 0.3, c2 is 0.5,
The sample size is 2000, total number of phenotypes is
and rho is 0.2. The power of all of the four methods is evaluated using 1,000 replicated
samples at a significance level of 0.05.
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4 Chapter 4
A Novel Statistical Method for Rare-variant Association Studies in General
Pedigrees

Both population-based and family-based designs are commonly used in genetic association
studies to identify rare variants that underlie complex diseases. For any type of study
design, the statistical power will be improved if rare variants can be enriched in the
samples. Family-based designs, with ascertainment based on phenotype, may enrich the
sample for causal rare variants and thus can be more powerful than population-based
designs. Therefore, it is important to develop family-based statistical methods that can
account for ascertainment. In this paper, we develop a novel statistical method for rarevariant association studies in general pedigrees for quantitative traits. This method uses a
retrospective view that treats the treat as fixed and the genotype as random, which allows
us to account for complex and undefined ascertainment of families. We then apply the
newly developed method to the Genetic Analysis Workshop 19 data set and compare the
power of the new method with two other methods for general pedigrees. The results show
that the newly proposed method increases power in most of the cases we consider, more
than the other methods.

4.1 Background
There is increasing interest in detecting associations between rare variants and complex
traits. Although statistical methods to detect common variant associations are well
developed, these variant-by-variant methods may not be optimal for detecting associations
with rare variants as a result of allelic heterogeneity as well as the extreme rarity of
individual variants (Li and Leal, 2008). Recently, several statistical method for detecting
associations of rare variants were developed for population-based designs, including the
cohort allelic sums test (Morgenthaler and Thilly, 2007), the combined multivariate and
collapsing method (Li and Leal, 2008), the weighted sum statistic (Madsen and Browning,
2009), the variable minor allele frequency threshold method (Price et al., 2010), the
adaptive sum test (Han and Pan, 2010), the set-up method (Hoffmann et al., 2010), the
sequence kernel association test (Wu et al., 2011), and the test for optimally weighted
combination of variants (Sha et al., 2012).
Meanwhile, quite a few statistical methods for rare variant association studies have been
developed for family-based designs. For any type of study design, the statistical power will
be improved if rare variants can be enriched in the samples. If one parent has a copy of a
rare allele, half of the offspring are expected to carry it, and, hence, variants that are rare
in the general population could be very common in certain families (Shi and Rao, 2011).
Therefore, family-based designs may plan an important role in rare-variant association
studies. Because of the importance of family-based designs in rare-variant association
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studies, several family-based rare-variant association methods for quantitative traits (Liu
and Leal, 2012; Chen et al., 2013; Svishcheva et al., 2014) and for qualitative traits (Zhu
et al., 2010; Feng et al., 2011; Zhu and Xiong, 2012) have been developed. However, most
of these methods were developed under the assumption of random ascertainment and
family-based designs with random ascertainment may not yield enrichment of rare variants.
To analyzing the sequencing data in general pedigrees provided by Genetic Analysis
Workshop 19 (GAW19), we proposed a novel method to the GAW19 data set, we
compared the power of the proposed method with that of two popular methods for familybased designs.
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4.2 Methods
Consider a sample of pedigrees with members in the
pedigree and a genomic
variants. Let
and
,…,
denote the trait value and
region with
genotypes of the variants in the genomic region for the
individual in the
pedigree.
∑
Let
denote the weighted combination of genotypes at the variants,
,…,
is a weight function.
where
∼

For given genotypes, we assume that
,…,

,

. Using the notation

, the retrospective likelihood is given by
Pr
Pr
∑ ∗ Pr
exp

,…,

,…,

|

Pr
∗

,…,

∑

∑ ∗ exp

∗

Pr
/2

∗

∑

Pr

/2

Pr

∗

where ∑ ∗ represents the summation of all possible genotypes. Based on the
0 is given by
test statistic for testing the null hypothesis :

, the score

/
∑

where
,…,

,

∑

∑

∑
∑

̅

(4.1)
Σ ∑

,

Φ

,

, Φ is twice the kinship coefficient of the

pedigree, and Σ
,
is the covariance matrix of the multiple variant
∑ ∑
genotype of one individual. Σ can be estimated by Σ ∑
. It is worth
is equivalent to the quantitative version of the retrospective
pointing out that
likelihood score statistic proposed by Schaid et al (2013).
Because rare variants are essentially independent, following Pan (2000) and Sha et al
(2012), we replace Σ by Σ
Σ . Then, the score test statistic
becomes
/

Σ

Φ
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∑ ∑
̅
. As a function of ,
where
when
Σ
and the maximum value of
is
Σ
the statistic of optimally weighted score test (OW-score) as
Σ

/

Φ

/

reaches its maximum
/∑
Φ . We define

/

Φ

where
is the
element of Σ and
is the
element of . Under the null
,
hypothesis,
is asymptotically distributed as a mixture of independent
can
statistics (Liu et al., 2007; Liu et al., 2009). Alternatively, the distribution of
be approximated by a Satterwaite approximation for the distribution of quadratic forms
distribution (Schaid et
(Wu et al., 2011; Kwee et al., 2008; Liu et al., 2008) or a scaled
al., 2013). We propose to approximate the distribution of
by a scaled
distribution with the scale and degree of freedom estimated by the expectation and
variance of
. Note that
∼ 0, Σ ∑
Φ
. We have
̂
and
.
ΣΣ
2
ΣΣ ΣΣ
Then, the scale is estimated as
/ 2 ̂ and the degree of freedom is estimated
as
2 ̂ / .
We compare the performance of our OW-score with (a) WS-score, the score test given by
equation (4.1) with weight given by Madsen and Browning (2009) and (b) famSKAT,
family-based sequence kernel association test given by Chen et al (2013).
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4.3 Results
We applied our proposed method as well as the WS-score test and famSKAT to the
simulated data from GAW19. All tests were conducted on 849 individuals, from 20
pedigrees, that had no missing genotypes or phenotypes. Sex, age, blood pressure
medication status, and smoking status were considered as covariates in this study. We were
aware of the underlying simulation model.
There are two related phenotypes, systolic blood pressure (SBP) and diastolic blood
pressure (DBP), at three time points. We considered the average of DBP at three time points
as the phenotype of interest in our analysis. We compared the power of the three tests (OWscore, WS-score, and famSKAT) to detect association between each of the top 14 genes
that influence the phenotype of interest. We used the variants between the first functional
single nucleotide polymorphism (SNP) and the last functional SNP in each gene in our
analysis. We did not consider CABP2 because the power of the three tests are essentially
the same due to the only one variant in this gene. To adjust the effects of the covariates on
the phenotype of interest, we first applied a linear model by regressing the phenotype of
interest on the covariates: sex, the average of age, the average of blood pressure medication
status, and the average of smoking status. The power comparisons based on the 200
replicated data sets are given in Table 4.1. Significance level is assessed at 5%. This table
shows that the OW-score test identified three genes with power greater than 40%,
famSKAT identified 1 gene with power greater than 40%, and the WS-score test could not
identify any genes with power greater than 40%. OW-score and famSKAT have different
power mainly because they use different weights. Let
and
denote the weights,
variant.
rescaled to the interval (0, 1), of the OW-score test and famSKAT for the
when minor allele frequency (MAF) is less than 0.01;
when
Then,
when MAF is greater than 0.05. The OWMAF is in the interval (0.01, 0.05);
score test has much higher power than famSKAT for RAI1 and REPIN1 because none of
the MAFs of the causal variants in RAI1 and REPIN1 are in the interval (0.01, 0.05).
We also evaluated the type I error rate of the proposed OW-score test. To evaluate the type
I error, we used 1000 blocks (100 variants in each block) from chromosome 5 that are far
from causal variants. In each block, we applied the OW-score test to each of the 200
replicates to test association between genotypes and the phenotype of interest. We obtained
one p-value for each replicate and each block. The type I errors of the proposed test were
0.04887, 0.00921, and 0.00131 at significance levels of 0.05, 0.01, and 0.001, respectively.
We also considered the average of SBP at three time points as the phenotype of interest,
which yielded similar results.
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4.4 Discussion
Next-generation sequencing technologies make directly testing rare variant association
possible. However, the development of powerful statistical methods for rare variant
associations studies is still underway. In this article, we proposed a novel statistical method
for rare-variant association studies based on general pedigrees for quantitative traits. The
application to the GAW19 data set showed that the proposed method has correct type I
error rate and is more powerful than the other two methods against which our method was
compared.
We described our method for quantitative traits. For qualitative traits, we can derive a score
test similar to that given by equation (4.1). However, the performance of the proposed
method for qualitative traits requires further investigation. Like many statistical methods
for rare variant associations studies, the proposed method can consider phenotype
measurement at only one time point. Statistical methods based on sequence data have been
developed for unrelated individuals that have phenotype measurements at multiple time
points (Wang et al., 2014). From a statistical standpoint, modeling using longitudinal
phenotypes is more informative than using phenotypes at a single time point and thus can
increase the power of an association test (Wang et al., 2014; Furlotte et al., 2012). Our
future work includes extension of the proposed method to longitudinal phenotypes.
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4.5 Conclusions
In this article, we developed a novel statistical method for rare variant association studies
in general pedigrees (randomly ascertainment pedigrees or ascertained pedigrees).
Application to GAW19 data set showed that the newly proposed method is more powerful
than the other two methods in most of the cases. Our new method uses a retrospective view,
which allows us to account for complex and undefined ascertainment of families. The
GAW19 data is based on randomly ascertained pedigrees. Results of applying our method
to GAW19 data showed that the proposed method has correct type I error based on random
ascertainment. When random ascertainment is violated and ascertainment is based on trait
values, the proposed method is expected to have correct type I error. If pedigrees are
ascertained because of extreme trait values, the proposed method is expected to have higher
power than methods based on randomly ascertained pedigrees.
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4.6 Table
Table 4.1. Power comparisons of the three tests using the average of DBP at three time
points as phenotypes. Significance level is assessed at 5%.
TOW  score
TWS score
FamSKAT
Genes
CGN
FLT3
LEPR
MAP4
MTRR
NRF1
PTTG1IP
RAI1
REPIN1
SLC35E2
TNN
ZFP37
ZNF443
ZNF544

0.135
0.005
0.05
0.175
0.465
0
0.02
0.845
0.915
0.005
0
0
0.01
0.005

0
0
0.015
0.185
0.005
0.005
0.145
0.005
0.05
0
0
0.005
0.015
0.015

0.035
0.08
0.065
0.425
0.06
0.035
0.06
0.155
0.085
0.05
0.035
0.005
0.195
0.06
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Appendix A: Supplementary Tables
Table A.1.1. Estimated type-I error rates for the eight methods under two variance models.
10, MAF is 0.3, and the sample size is 1,000. is
The total number of phenotypes is
the significance level.
Type-I error rates
Variance model 1
Methods

0.05

Variance model 2
0.01

0.05

0.01

OB

0.052

0.013

0.046

0.011

CV

0.056

0.006

0.042

0.010

OW

0.047

0.006

0.046

0.009

TATES

0.060

0.008

0.040

0.007

MANOVA

0.047

0.006

0.046

0.009

CCA

0.045

0.009

0.046

0.011

PCH

0.048

0.006

0.048

0.010

MultiPhen

0.049

0.007

0.049

0.012
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Table A.1.2. Estimated type-I error rates for the eight methods under two variance models.
40, MAF is 0.3, and the sample size is 1,000. is
The total number of phenotypes is
the significance level.
Type-I error rates
Variance model 1
Methods

0.05

Variance model 2
0.01

0.05

0.01

OB

0.038

0.007

0.060

0.011

CV

0.051

0.010

0.058

0.014

OW

0.045

0.011

0.056

0.015

TATES

0.045

0.012

0.051

0.011

MANOVA

0.046

0.011

0.063

0.016

CCA

0.046

0.012

0.063

0.016

PCH

0.045

0.011

0.057

0.017

MultiPhen

0.055

0.015

0.076

0.015
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Table A.1.3. Estimated type-I error rates for the eight methods under two variance models.
10, MAF is 0.1, and the sample size is 1,000. is
The total number of phenotypes is
the significance level.
Type-I error rates
Variance model 1
Methods

0.05

Variance model 2
0.01

0.05

0.01

OB

0.051

0.005

0.056

0.014

CV

0.043

0.009

0.040

0.009

OW

0.044

0.006

0.041

0.009

TATES

0.048

0.010

0.047

0.007

MANOVA

0.045

0.007

0.041

0.010

CCA

0.042

0.008

0.039

0.010

PCH

0.045

0.006

0.039

0.011

MultiPhen

0.046

0.008

0.044

0.009
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Table A.1.4. Estimated type-I error rates for the eight methods under two variance models.
20, MAF is 0.1, and the sample size is 1,000. is
The total number of phenotypes is
the significance level.
Type-I error rates
Variance model 1
Methods

0.05

Variance model 2
0.01

0.05

0.01

OB

0.043

0.010

0.046

0.008

CV

0.058

0.012

0.050

0.010

OW

0.059

0.013

0.049

0.008

TATES

0.047

0.008

0.052

0.018

MANOVA

0.059

0.014

0.051

0.008

CCA

0.059

0.014

0.052

0.009

PCH

0.059

0.014

0.048

0.007

MultiPhen

0.065

0.013

0.054

0.011
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Table A.1.5. Estimated type-I error rates for the eight methods under two variance models.
40, MAF is 0.1, and the sample size is 1,000. is
The total number of phenotypes is
the significance level.
Type-I error rates
Variance model 1
Methods

0.05

Variance model 2
0.01

0.05

0.01

OB

0.048

0.009

0.050

0.009

CV

0.044

0.007

0.053

0.013

OW

0.037

0.004

0.055

0.012

TATES

0.042

0.010

0.058

0.014

MANOVA

0.042

0.004

0.060

0.017

CCA

0.046

0.005

0.064

0.015

PCH

0.039

0.006

0.059

0.017

MultiPhen

0.053

0.008

0.072

0.016
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Table A.2.1. Significant SNPs and the corresponding p-values in the analysis of
COPDGene using the principal components (PCs) of phenotypes. The p-values of
WCmulP are evaluated using 10 permutations, the p-values of SHet are evaluated using
10 permutations. The grayed-out p-values indicate the p-values 5 10 .
Chr

Variant identifier

WCmulP

SHet

Score

MultiPhen

CCA

TATES

OB

4
4
4
4
4
15
15
15
15
15
15
15
15
15
15
15

rs1512282
rs1032297
rs1489759
rs1980057
rs7655625
rs16969968
rs1051730
rs12914385
rs8040868
rs951266
rs8034191
rs2036527
rs931794
rs2568494
rs17483721
rs17483929

0
0
0
0
0
0
0
0
0
0
0
0
0
4.10E-08
5.00E-08
4.00E-08

0
0
0
0
0
0
0
0
0
0
0
0
0
6.0E-08
2.2E-07
9.0E-08

1.33E-09
1.18E-13
2.22E-16
1.11E-16
2.22E-16
7.84E-12
8.23E-12
5.60E-13
8.47E-13
9.82E-12
1.04E-10
2.13E-10
1.04E-10
6.97E-08
1.25E-07
8.89E-08

9.28E-10
2.19E-13
3.14E-16
2.16E-16
2.68E-16
3.93E-12
4.02E-12
5.10E-13
1.10E-12
4.85E-12
3.19E-11
7.79E-11
3.29E-11
2.58E-08
6.10E-08
3.89E-08

1.19E-09
1.40E-13
2.22E-16
1.11E-16
1.11E-16
5.42E-12
5.63E-12
5.53E-13
1.05E-12
7.16E-12
7.56E-11
1.52E-10
7.71E-11
6.01E-08
1.17E-07
8.08E-08

2.85E-06
2.58E-09
3.19E-12
9.21E-13
1.80E-12
6.56E-07
5.43E-07
4.94E-07
3.42E-07
6.65E-07
4.19E-06
9.02E-06
2.47E-05
3.01E-04
2.86E-04
2.94E-04

1.01E-04
6.91E-07
2.32E-08
1.72E-08
1.63E-08
1.99E-03
1.35E-03
4.64E-05
2.58E-04
2.96E-03
6.25E-03
5.36E-03
1.66E-02
3.69E-02
2.64E-02
3.28E-02
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Table A.2.2. The structures of
of phenotypes is 8.

and cov

1

for different numbers of factors when number

2
1
1
1
1
0
0
0
0

1
1
1
1
1
1
1
1

4

0
0
0
0
1
1
1
1

1
1
0
0
0
0
0
0

1

1
cov

⋮

1
⋮

⋯
⋯
⋱ ⋮
⋯ 1

0
0
0
0
0
0
1
1

0
0
0
0
1
1
0
0

1

1
1

0
0
1
1
0
0
0
0

1

1

1

1
1

1

1

1
1
1

1
1
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Appendix B: Supplementary Figures
Figure B.1.1. Power comparisons of the eight methods as a function of heritability for the
10, rho
six mean models under variance model 1. The total number of phenotypes is
is 0.1, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure B.1.2. Power comparisons of the eight methods as a function of heritability for the
10, rho
six mean models under variance model 2. The total number of phenotypes is
is 0.1, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure B.1.3. Power comparisons of the seven methods as a function of heritability for the
40, rho
six mean models under variance model 1. The total number of phenotypes is
is 0.1, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure B.1.4. Power comparisons of the seven methods as a function of heritability for the
40, rho
six mean models under variance model 2. The total number of phenotypes is
is 0.1, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure B.1.5. Power comparisons of the eight methods as a function of rho for the six mean
10, heritability is
models under variance model 1. The total number of phenotypes is
0.01, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.

81

Figure B.1.6. Power comparisons of the eight methods as a function of rho for the six mean
10, heritability is
models under variance model 2. The total number of phenotypes is
0.01, MAF is 0.3, and the sample size is 1,000. Significance is assessed at the 5% level.
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Figure B.1.7. Power comparisons of the seven methods as a function of rho for the six
40 ,
mean models under variance model 1. The total number of phenotypes is
heritability is 0.01, MAF is 0.3, and the sample size is 1,000. Significance is assessed at
the 5% level.
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Figure B.1.8. Power comparisons of the seven methods as a function of rho for the six
40 ,
mean models under variance model 2. The total number of phenotypes is
heritability is 0.01, MAF is 0.3, and the sample size is 1,000. Significance is assessed at
the 5% level.
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Figure B.1.9. Power comparisons of the eight methods as a function of MAF for the six
20 ,
mean models under variance model 1. The total number of phenotypes is
heritability is 0.02, rho is 0.1, and the sample size is 1,000. Significance is assessed at the
5% level.
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Figure B.1.10. Power comparisons of the eight methods as a function of MAF for the six
20 ,
mean models under variance model 2. The total number of phenotypes is
heritability is 0.02, rho is 0.1, and the sample size is 1,000. Significance is assessed at the
5% level.
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Figure B.1.11. Power comparisons of the six methods as a function of heritability for the
20, rho
six mean models under variance model 1. The total number of phenotypes is
is 0.1, MAF is 0.3, and sample size is 1000. Significance level is 5×10-8.
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Figure B.1.12. Power comparisons of the six methods as a function of heritability for the
20, rho
six mean models under variance model 2. The total number of phenotypes is
is 0.1, MAF is 0.3, and sample size is 1000. Significance level is 5×10-8.
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Figure B.1.13. Power comparisons of the six methods as a function of rho for the six mean
20, MAF is 0.3,
models under variance model 1. The total number of phenotypes is
and sample size is 1000. Significance level is 5×10-8.

89

Figure B.1.14. Power comparisons of the six methods as a function of rho for the six mean
20, MAF is 0.3,
models under variance model 2. The total number of phenotypes is
and sample size is 1000. Significance level is 5×10-8.
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Figure B.2.1. Power comparisons of the seven methods as a function of for the six
models using the principal components (PCs) of phenotypes. The total number of
phenotypes is
8,
0.5,
0.1, and
0.3. The p-values of WCmulP
and SHet are evaluated using 1,000 permutations. The power of all of the seven methods
is evaluated using 1,000 replicated samples at a significance level of 0.01.
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Figure B.2.2. Power comparisons of the seven methods as a function of for the six
models using the principal components (PCs) of phenotypes. The total number of
phenotypes is
16,
0.5,
0.1, and
0.3. The p-values of WCmulP
and SHet are evaluated using 1,000 permutations. The power of the seven methods is
evaluated using 1,000 replicated samples at a significance level of 0.01.

92

for the six
Figure B.2.3. Power comparisons of the seven methods as a function of
models using the principal components (PCs) of the phenotypes. The total number of
phenotypes is
8,
0.1, and
0.3. The p-values of WCmulP and SHet are
evaluated using 1,000 permutations, the p-values of other methods are evaluated using
asymptotic distribution. The power of all of the seven methods is evaluated using 1,000
replicated samples at a significance level of 0.01.
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for the six
Figure B.2.4. Power comparisons of the seven methods as a function of
models using the principal components (PCs) of the phenotypes. The total number of
phenotypes is
16,
0.1, and
0.3. The p-values of WCmulP and SHet
are evaluated using 1,000 permutations, the p-values of other methods are evaluated using
asymptotic distribution. The power of all of the seven methods is evaluated using 1,000
replicated samples at a significance level of 0.01.
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Figure B.2.5. Power comparisons of the seven methods as a function of for the six
models. The total number of phenotypes is
8,
0.5,
0.1, and
0.3.
The p-values of WCmulP and SHet are evaluated using 100,000 permutations. The power
of all of the seven methods is evaluated using 1,000 replicated samples at a significance
level of 5 10 .
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Figure B.2.6. The correlation matrix plot of the 7 COPD-related phenotypes.
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